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Abstract 
Studies have demonstrated a correlation between stress and an increased risk of 
breast cancer. Neuropeptide Y (NPY) is up- regulated in chronic stress and induces 
proliferation and chemotaxis of 4T1 breast cancer cells via Y5 receptor (Y5R) activation. In 
the studies performed in this thesis, we characterize NPY-Y5R as a regulatory system that 
promotes breast cancer metastasis. We compared three cancer cell sublines derived from the 
same murine mammary fat pad tumour, that greatly differ in metastatic potential (67NR, 
168FARN, and 4T1) in addition to a 4T1-Y5R knockdown established in our labs. In this 
thesis we demonstrate significance of up-regulation and cytoplasmic localization of Y5R to 
support an aggressively metastasizing breast cancer cell line. Using cellular MRI we 
characterized the knockdown of Y5R to alter breast carcinogenesis and metastasis. In this 
respect, NPY and its Y5 receptor could be therapeutic targets to combat breast cancer 
metastasis. 
Keywords: Neuropeptide Y; Y5 receptor; stress; breast cancer; metastasis; 4T1-derived cell 
lines; cellular MRI; mouse model   
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Chapter 1- Background 
1.1 Breast cancer and metastasis  
Breast cancer is the second most common form of cancer death in females.1 The 98.8% 5-year 
survival rate of localized breast cancer drops to 26.3% when the breast cancer is metastastic at 
diagnosis.2 Breast cancer commonly metastasizes to the lung, liver, bone, and brain.3  
Cancer metastasis is the dissemination of cells from the primary tumour via the lymphatics or 
hematogenously and proliferation at a distant site. Metastasis is an inefficient process supported 
by a high number of circulating cancer cells that do not result in the formation of a tumour.4 This 
inefficiency is due to the conditions in the metastatic cascade that the cell must withstand prior to 
arresting in an alternate site. Cells must successfully intravasate from the primary site into the 
vasculature, withstand shear forces in the circulation, extravasate into an alternate site and 
successfully form micrometastases in this new microenvironment.5 The primary characteristics 
that determine successful metastasis of a cancer cell fate require further investigation.  
1.2 Stress and breast cancer 
In a study of 1,601 breast cancer patients, 180 (11.2%) had triple negative breast cancer. Patients 
with triple negative breast cancer had an increased likelihood of distant recurrence and increased 
risk of death within 5 years of diagnosis.6 In triple negative breast cancers, negative for the 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 
2 (HER-2), treatment with classic hormone therapy and HER-2 directed therapy is futile. The 
sole current therapy for triple negative breast cancer is cytotoxic chemotherapy. Therefore, a 
novel target for therapy to treat triple-negative breast cancer is required. 
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Studies have demonstrated a correlation between elevated stress levels and poor prognosis and 
survival in patients with breast cancer.7–11 Independent of body mass index, weight change, 
alcohol use, smoking, and physical activity, there is a two-fold increase in breast cancer 
recurrence after a single stressful life event, such as a disruption of marriage due to divorce, 
separation, or death of a spouse, that do not seem to be mediated or altered by perceptions of 
one’s daily stress, adverse personality, or pessimistic attitude.12 In a retrospective study of 94 
women with breast cancer recurrence or metastasis, planned comparisons revealed a significantly 
longer disease-free interval amongst women who had reported no traumatic or stressful life 
events compared to those who had experienced one or more, such as abandonment or close 
member of kin dying.13 
1.3 Stress-induced release of Neuropeptide Y 
Neuropeptide Y (NPY) is most widely expressed in the central and peripheral nervous systems 
and plays a major role in cognitive function, feeding patterns, and cardiovascular regulation.14 
NPY elicits its ubiquitous effects by binding to G- Protein Coupled Receptors, Y1R, Y2R, Y4R, 
Y5R, and Y6R, which have been cloned in mammals.15 NPY is a sympathetic neurotransmitter 
that is released in greater quantities during chronic stress and in response to a life-threatening 
stressor from sympathetic nerves, adrenal medulla and platelets.16,17 Cold exposure significantly 
stimulates the release of NPY in both humans and rodents.18,19 Additionally, exposure of to an 
aggressor mouse stimulates the release of NPY in rodents.17 In clinical trials, Y5R antagonist, 
MK-0577, proved insufficient as a monotherapy to treat obesity but displayed favourable clinical 
safety.20  
The pleiotropic influence of NPY varies between males and females. Basal sympathetic nerve 
activity is lower in females compared to males.21 Jackson et al. demonstrated that estrogen has 
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the capacity to blunt Y1R activation in skeletal muscle.22 Local noradrenergic mechanisms are 
NPY-Y1R mediated and can be modulated by reproductive hormone activity. When estrogen and 
progesterone are elevated during the luteal phase, persistent vasoconstriction, is observed. 
Furthermore, when estrogen and progesterone are low during the follicular phase 
vasoconstriction is abolished. This mechanism is NPY mediated, validated by consistent 
vasomotor activity with α and β receptor blockade23 Additionally, Glenn et al. demonstrated that 
peptidases, that enhance Y2R and Y5R binding, may be more active in females compared to 
males.24  
NPY vasoactive effects are not limited to periods of chronic and intense stress. NPY contributes 
to maintaining baseline vasomotor tone and sympathetically induced vasoconstriction, supported 
by high circulating levels of NPY in patients with hypertension.25 Additionally, the ratio of 
released NPY and norepinephrine (NE) from sympathetic nerves is consistent, independent of 
the degree of sympathetic stimulation, both contributing to basal vasomotor tone.26  
1.4 Neuropeptide Y Receptors Trafficking and Localization 
Neuropeptide Y1R-Y6R are Gi-protein coupled receptors with seven transmembrane loops with 
the capacity to induce a multitude of downstream cascading effects upon NPY binding. Post-
activation, NPY receptors adopt a conformation causing the alpha subunit to convert guanosine 
diphosphoate (GDP) to guanosine triphosphate (GTP). As a result Neuropeptide Y receptors 
regulate transcription primarily via phosphoinositide 3 (PI3) kinase activity.27 Downstream 
effector extracellular signal-regulated kinases (ERK) activity and mitogen-activated protein 
kinases (MAPK) are induced and cyclic adenosine monophosphate (cAMP)-dependent pathways 
are inhibited, dually contributing to transcriptional regulation. Independent of PI3 kinase activity, 
insulin growth factor receptor transactivation by NPY receptors is required to activate ERK.27 
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Figure 1.4.1. NPY-Y receptor Molecular Mechanism. Neuropeptide Y can activate Y1R- Y6R 
via binding to the seven transmembrane Gi-protein coupled receptors. Transcriptional regulation 
primarily occurs via PI3K and ERK activation and cAMP inhibition.  
The affinity of NPY to receptors is regulated by the proteolytic cleavage of NPY by dipeptidyl 
peptidase IV (DPPIV) and aminopeptidase P (APP), the resulting cleaved form of NPY binds 
preferentially to Y2R and Y5R compared to Y1R.28 Previous studies have shown that activated 
NPY Y1 and Y2 receptors internalize via clathrin-coated pits within the cytoplasm and close to 
the nucleus in human embryonic kidney cells29. These receptors return to the plasma membrane 
by cytosolic β-arrestins directly or transiently enter the rough endoplasmic reticulum.30. In 
contrast to Y1R and Y2R, Y5R internalizes less, slower, and requires greater agonist 
stimulation29. Of particular interest, human Y1R and Y5R are transcribed in opposite directions 
from a common promoter region on chromosome 4q31-q32.31  
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Y5R is expressed in a tissue-specific manner, primarily in the colon, ovaries, spleen, and testes. 
It is expressed as two isoforms, short and long, with the short form dominating in expression 
quantitatively. Therefore, it is suggested that alternative splicing of the 5’UTR could regulate the 
level of transcription of the receptor in a tissue specific –manner.32 Y5R has a very long third 
intracellular loop compared to Y1R, Y2R, and Y4R.29 Y5R has two binding sites with the 
potential to bind high or low affinity to its ligands, NPY, NPY3-36, PYY, PYY3-36, and PP. 
Sheriff et al. postulated that the activation of Y5R in normal physiological conditions occurs by 
binding the high affinity site and the activation of Y5R in pathophysiological conditions occurs 
by binding the low affinity site.33 
1.5 Neuropeptide Y and the Immune System 
NPY and the immune system modulate each other’s activity bi-directionally. NPY secretion has 
been found to be increased in transgenic mice that over-express tumour necrosis factor (TNFα) 
and inhibited in human astrocytes by interleukin (IL)-1β.29,30 NPY plays a prominent role in 
immune modulator release, Natural Killer Cell (NK) activity, T helper cell differentiation, B cell 
homeostasis, and leukocyte trafficking. NPY can elicit its effects by binding and activating Y1R, 
Y4R, or Y5R expressed by neutrophils and Y1R expressed by both T cells and granulocytes.31,32 
NPY suppresses NK cell activity in a dose-dependent manner in vitro, as well as in the rat spleen 
in vivo.33,34 Additionally, NPY supports a shift to T-Helper 2 (Th2) cells through stimulation of 
IL-4 secretion, stimulating the conversion of macrophages to anti-inflammatory M2 cells, which 
stimulate tumour growth.35,36 Furthermore, NPY induces increased chemotaxis of monocytes and 
preferential mobilization of leukocytes.37,38 Therefore, previous studies have suggested indirect 
methods of how stress, molecularly transduced via NPY, can affect cancer progression via 
immunosuppression.  
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1.6 Neuropeptide Y5R in cancer 
Neuropeptide Y5R is expressed in cancer cell lines including breast and brain xenograft 
models.39-42 In neuroblastoma, Y5R is up-regulated via brain-derived neurotrophic factor 
(BDNF). Of particular interest, BDNF was found to induce internalization of Y5R, contributing 
to chemo-resistant properties. Furthermore, chemotherapeutic treatment-induced cellular stress 
and increased NPY release resulting in increased Y5R expression. Administration of a Y5R 
antagonist sensitized the cells to chemotherapy, permitting tumour cell death.39 In Ewing 
sarcoma, hypoxia shifts the inhibitory actions of NPY, mediated via Y1R and Y5R, to 
proliferative, migratory, and angiogenic via Y2R and Y5R activation by increasing DPPIV 
activity.40  
1.6.1 NPY-Y5R system and breast cancer 
The lateral and anterior cutaneous branches of the second and sixth intercostal nerves 
sympathetically innervate the mammary gland, smooth muscle of the areola, skin, and breast 
blood vessels.41 In this respect, the breast microenvironment is susceptible to the alterations in 
NPY flux induced by chronic stress. This susceptibility has the potential to have a negative 
impact on women with family histories of breast cancer, who have an increased basal release of 
sympathetic neurotransmitters in response to daily stressors.42 In breast tumour tissue, the NPY 
precursor, pre-pro-NPY, is up-regulated accompanied with a down-regulation of NPY (1-36), 
however the DPPIV processed form of NPY (3-36) was not assayed.43 Human breast carcinoma 
cell lines MCF-7, T47D, MDA MB-231, MDA MB-468, HS578T, BT-549 express significantly 
more Y5R than Y1R and Y2R.33 Immunohistochemical observation has revealed the 
predominant expression of Y5R with respect to Y1R and Y2R in 4T1 cells grown in murine 
mammary fatpad.44  
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1.6.1.1 Proliferation 
The rate of cancer cell proliferation is indicative of breast cancer aggression and has an increased 
potential to develop into clinically relevant tumours. NPY has been found to be a potent mitogen 
in both human breast and murine mammary cancer cells.33,44 The Jackson lab previously 
evaluated the independent contributions of Y1R, Y2R, and Y5R on NPY-induced proliferation.  
Solely, Y5R-antagonism has the capacity to inhibit the NPY-induced proliferation of 4T1 cancer 
cells.44 Sheriff et al. demonstrated the significant proliferative effects of NPY on BT-549 cells, 
which is inhibited by Y5R antagonism.33 
1.6.1.2 Migration 
The capacity of malignant cancer cells to migrate to neighbouring tissue and vasculature is a pre-
requisite for metastasis. Sheriff et al. demonstrated that the triple negative human MDA-MB-231 
cells have an increased propensity to migrate due to Y5R-mediated NPY stimulation.33 Medeiros 
et al. demonstrated that NPY-induced chemotaxis of 4T1 cells is primarily via Y2R and Y5R 
stimulation in a concentration-dependent manner. This is supported by Y1R antagonism eliciting 
no effect on NPY-induced chemotaxis of 4T1 cells, in contrast to migratory inhibition via Y5R 
antagonism.44   
1.6.1.3 Angiogenesis 
Neuropeptide Y stimulates the expression of vascular endothelial growth factor (VEGF), one of 
the primary regulatory pro-angiogenic factors in the tumour microenvironment. At physiological 
concentrations of NPY-conditioned media from 4T1 and MDA-MB-231 human breast cancer 
cells, there was a significant increase in VEGF expression with the capacity to induce 
angiogenesis in vitro evaluated by an endothelial tube formation assay. Angiogenesis was 
specifically induced by Y5R agonist treatment, in contrast to Y1R and Y2R activation. This 
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experiment elucidated the paracrine mechanism of NPY to activate Y5R inducing the release of 
pro-angiogenic VEGF.45  
1.6.1.4 Tumourigenicity and Metastasis 
Neuropeptide Y is robustly expressed in MFP tumours supplied by sympathetic innervation. The 
Jackson lab has chemically-induced sympathectomy, via 6-hydroxydopamine (6-OHDA) 
treatment, and found a reduction in mammary fatpad tumour burden by up to 50%.44 
Furthermore, oral administration of 90mg/kg of a specific Y5R antagonist TAC557, significantly 
attenuated tumour growth and reduced metastatic lung lesion burden.46  
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1.7 4T1-derived Cell Lines 
In addition to the study of cancer in vitro, cancer cell behaviour should be examined within a 
well-recapitulated tumour microenvironment. The 4T1-derived murine mammary carcinoma cell 
lines are syngeneic immune competent models and thereby permit this evaluation as opposed to 
human cell xenograft models in immune-compromised mice. Identification of specific 
biomarkers indicative of metastatic ability would be ideal to determine the fate and risk potential 
of cancer cells. The 67NR, 168 FARN, and 4T1 cell lines originate from the same murine 
mammary fat pad tumour but differ in metastatic potential.47 The 67NR line was established by 
re-plating a monolayer of cells followed by subsequent passaging on gelatin substratum, 
resulting in a retained elongated spindle morphology over 40 passages.48 The 168FARN line was 
established by re-plating the primary cells onto a non-gelatinized dish and were selected for their 
fibroblastic morphology that was retained for 20 passages. 48 The 4T1 cell line was formed by 
repeated and sequential selection of lung metastases from intravenous injection.49  
67NR cells solely proliferate in the mammary fat pad and do not intravasate to the circulation to 
metastasize. 168FARN cells have the capacity to disseminate to the lymph node and do not 
metastasize to other parts of the body, in this sense intravasation is fulfilled without resulting in 
extravasation. 4T1 cells are able to aggressively metastasize from the primary mammary fatpad 
to the lungs, liver, bone and brain primarily hematogenously.47  
The 4T1 cell line has been evaluated to effectively model the metastatic progression that is 
clinically observed, with a more accurate recapitulation of human metastasis compared to 
xenograft models.50 Human stage IV breast cancer is classified by the presence of metastases in 
distant organs.51 The features of human stage IV breast cancer can include: (1) the presence of 
edema and ulcerations of the skin in and around the primary tumor burden (2) the extension of 
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the primary tumor to the chest cavity lining, (3) the presence of metastatic cells in the draining 
lymph nodes.51 All these features are observed when 4T1 primary tumours exceed 3mm in 
diameter.50  
Despite originating from the same tumour, the cell lines vary morphologically in culture. 67NR 
cells form a network-like lattice, in contrast to 168FARN and 4T1 cells that possess a 
fibroblastic appearance in culture.47 The cells innately differ in proliferation in vitro; 4T1 cells 
have a doubling time of 13.6+1.5h, 168FARN cells have a doubling time of 21+3.9h, and 67NR 
cells have a doubling time of 22.4+1.8h.48,49 The growth of the latter two under the influence of 
NPY-stimulation is yet to be elucidated.  
The inherent phenotypic properties of 67NR and 168FARN cells differ in vitro. 67NR cells 
possess comparable adherent capability to 168FARN cells, with diminished migratory potential, 
but enhanced invasive properties. Despite the enhanced invasive ability of 67NR cells in vitro, 
they do not metastasize in vivo.53 
1.8 shRNA knockdown  
shRNA knockdown is achieved through successful vector transfection, transcription of shRNA, 
and subsequent sequestration and degradation of the target mRNA.54 Vector transfection permits 
exploitation of the cellular transcription machinery to transcribe the shRNA. Knockdown can 
also be achieved via exogenously introduced and processed siRNA. shRNA is more efficient as 
it integrates into the endogenous miRNA pathway and has enhanced loading onto the RNA-
induced silencing complex (RISC).55 shRNA results in a knockdown of the targeted mRNA 
expression as opposed to a knockout, which alters the genomic sequence.56 Knockout of genomic 
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DNA has the potential to cause detrimental cellular defects due to off-target sequence 
deletions.57   
Down-regulation of key proteins and receptors can elucidate their contribution to carcinogenesis 
and metastasis. shRNA has been employed to degrade HER2/neu protein levels, resulting in 
suppression of migration and invasion of breast cancer cells in vitro without alteration of cell 
viability.58 shRNA has also been used to reduce the expression of epidermal growth factor 
receptor (EGFR) in human breast adenocarcinoma MDA-MB-231 cells by 60% and inhibit 
mammary fat pad tumour growth and VEGF secretion in vivo.59 Furthermore, shRNA can be 
used to reveal cellular mechanisms in response to therapy. shRNA against metastasis associated-
1 (MTA-1) recovered the expression of estrogen receptor (ER) alpha, permitting sensitization of 
MDA-MB-231 cells to estrogen therapy.60  
In this thesis, we investigate the role of Y5R in aggressively metastasizing 4T1 cells by knocking 
down Y5R expression facilitated by shRNA. Using this knockdown, we evaluate the contribution 
of Y5R to breast cancer cell proliferation and metastasis.  
1.9 MRI for evaluating tumour development and metastasis 
Magnetic Resonance Imaging (MRI) relies on the properties of hydrogen atoms (protons) to 
generate an image.  A strong magnetic field causes proton alignment within a subject. A 
radiofrequency (RF) transmitter is subsequently turned on then off, causing the protons to be 
energized then relaxed, respectively. Energy is emitted from protons when they relax to their 
state of equilibrium. The emitted energy produces a signal that is detected and translated by 
advanced computer processing. Image contrast exploits the variable relaxation rates of protons in 
biological tissue. T1-, T2-and T2*-weighted images are common image contrasts.  
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MRI has been widely used to study preclinical mouse models of cancer.61–66 Cancer tissue has 
different relaxation rates in contrast with normal tissue, permitting MRI to play a significant role 
in the detection, staging and characterization of cancer.67 Tumors may appear as either hypo-or 
hyper-intense regions relative to normal tissue, depending on the composition and pulse 
sequence used.  MRI provides excellent three dimensional anatomic detail and sensitivity to 
permit tumour size quantification and location, in addition to edema, hemorrhage, and necrosis.65  
In vivo MRI permits non-invasive observation of tumors and metastases longitudinally and in 
three dimensions and all spatial orientations.  3D MRI permits in vivo tumour size quantification, 
in comparison to histological tissue sections, which must account for shrinkage and deformation 
due to the chemical processing, or caliper measurements that assume symmetrical tumour 
volume. MRI permits comprehensive analysis of tumour growth rate, tumour development and 
metastasis, in contrast to traditional histology.  
Contrast agents are employed to enhance regions of interest by shortening both the T1 and T2 
times of surrounding tissues, in general affecting one relaxation more than the other. 
Paramagnetic contrast agents induce T1 shortening and include gadolinium-(Gd) based and 
manganese (Mn) based agents that are detected as bright signals on T1-weighted images. 
Superparamagnetic contrast agents all consist of iron-oxide cores and induce T2-shortening 
resulting in signal loss or hypointensity. 
MRI post-Gd is often used to assess the integrity of the blood-brain-barrier (BBB) and in cancer 
imaging the blood-tumour-barrier. Gd is a small-sized contrast agent that is administered 
intravenously that provides enhancement of highly perfused tissue and vessel permeability. The 
Foster lab has investigated how the BBB permeability is dynamic in accordance with the 
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progression of breast cancer metastasis. Gd-enhanced contrast MRI is widely recognized as the 
most accurate diagnostic tool in the detection of brain metastases, however the Foster lab found 
many metastases detected did not exhibit Gadopentetic acid (Gd-DTPA) enhancement and were 
only detectable using bSSFP.64,65  The Foster lab was the first to use 3T MRI and employ bSSFP 
to monitor the development of melanoma brain metastases longitudinally. They found bSSFP 
imaging permits detection of brain metastases at early time points that can be undetected on T1-
weighted spin echo (T1wSE) images.64  
Post-Gd MRI has also been used to enhance contrast in mouse models of breast cancer.  Gd MRI 
can be used to identify aggressive tumours, due to high angiogenic activity required to maintain 
blood supply to highly proliferative tumour cells. Gd enhancement also permits differentiation 
between ER positive luminal breast tumours and triple negative basal breast tumours.69 Gd MRI 
has provided insight in the alterations of tumour vasculature with estradiol deprivation in luminal 
tumours in a murine orthotopic xenograft model, while basal tumours remain unaffected by 
estradiol deprivation.70 Angiogenesis can be indicative of a developed tumour, however the 
fluid-filled core of an aggressively metastasizing large tumour can inhibit Gd transport.71 
1.10 Iron oxide labeling of cells for MRI 
Cellular MRI can be achieved by pre-labeling cells with iron oxide nanoparticles prior to their 
administration. Iron oxide contrast agents create negative contrast in T2-or T2*-weighted proton 
MR images. The presence of intracellular iron causes a distortion in the local magnetic field 
resulting in abnormal signal hypointensity in iron-sensitive images. Therefore, iron-labeled cells 
appear as regions of signal loss, or black holes in the MR images. The reduced transverse (T2) 
and effective transverse (T2*) relaxation times of nearby nuclei extends to signal loss that 
occupies more space than the contrast agent itself resulting in a “blooming artifact.”  
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Iron oxide nanoparticles are classified on the basis of size; ultra small superparamagnetic iron 
oxide nanoparticles (USPIO), standard magnetic superparamagnetic iron oxide particles (SPIO), 
or micron-size superparamagnetic iron oxide nanoparticles (MPIO). USPIO particles are 10-
20nm in diameter, SPIO particles are 50-100nm in diameter, and MPIO particles are 
approximately 1-5µm in diameter.72 
A variety of cell types can be easily loaded with iron oxide nanoparticles by simple co-
incubation. Nanoparticle uptake is mediated by scavenger receptors, receptor-independent 
macropinocytosis, and clathrin–mediated uptake leading to iron oxide storage in endosomes.73 
Cancer cells readily uptake MPIOs, for example B16F10 melanoma cells have an uptake 
efficiency of 100% with an average iron content of 35pg of Fe/cell.65 Studies show that there is 
minimal impact on cell function or phenotype at a wide range of iron loading levels.74,75 
Specifically, MPIO or SPIO cancer cell labeling has no discernable effect on viability, in vitro 
proliferation, cell apoptosis, necrosis, or in vivo metastasis compared to unlabeled cells.62,65,76 
Heyn et al. have demonstrated that even single iron-labeled cells can be detected in vivo.  Single 
cell detection was permitted due to the aforementioned blooming artifact whereby cancer cells of 
approximately 20µm in diameter elicited a signal void of 300µm diameter in the MR image.62  
1.11 Cancer Cell Imaging with MRI 
Very few groups have used cellular MRI to study cancer cells because the iron label is diluted 
over time in proliferative cells, leading to label loss and therefore loss of cell detection.  The 
Foster lab reported that intracellular iron disappeared after 5 days, when visualized with 
photomicrographs, corresponding to the sixth generation of daughter cells.65 Similarly, using 
flow cytometry and Perls’ Prussian Blue (PPB) staining, Economopoulos et al. found that less 
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than 50% of cells retained detectable quantities of iron four days post-labeling and only 1-2.5% 
remained labeled by day 10.61  
However, the dilution of iron by cancer cells can be exploited to provide insight in regards to 
their proliferative status. The Foster lab has demonstrated that cancer cells that are non-
proliferative, or slowly-cycling, will retain the iron label and the fate of these cells can be tracked 
with MRI.61 The Foster lab was the first to identify non-proliferative cancer cells in the brain 
using iron oxide labeling techniques. Using this effective cell tracking technique, human breast 
cancer MDA-MB-231 cells were characterized as proliferative (1.5%), transiently proliferative 
(94%), and non-proliferative (4.5%) of the original tumour imaged at day 0.62 Non-proliferative 
cells are considered dormant in a state of cell cycle arrest with the potential to form metastases 
and are likely the culprit of recurrence.  
Magnitzsky et al. exploited iron label retention in slowly proliferative melanoma cells 
subcutaneously implanted and found a positive correlation with a biomarker, JARID1B. When 
the tumours reached 1cm3 after 5-6 weeks, MR imaging demonstrated that iron-retaining cells 
were localized close to the tumour vasculature elucidating the localization of slowly proliferative 
cells.63  
Townson et al. used cellular MRI to monitor iron-labeled metastatic melanoma cells.80 B16F1 
cells were iron-labeled and injected via the mesenteric vein. Mice were treated with either 
doxorubicin or vehicle. MRI was used to quantify both the number of liver metastases and 
persisting iron-labeled cells. Doxorubicin decreased metastatic growth but did not decrease the 
existing metastatic cell populations. This important work showed the ability to assess the effect 
of treatment on both proliferative and non-proliferative cell populations and pointed to the lack 
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of effect on non-proliferating cells as a factor, which may be responsible for failure rates in 
treatment of metastatic disease.77 
Economopolous et al. used cellular MRI to monitor the development of iron-labeled primary 
MDA-MB-231 mammary fat pad tumours and metastasis to the lymph nodes.64 Over time, the 
signal loss associated with the iron-labeled cancer cells was redistributed throughout the tumour 
as the cancer cells proliferated. After 4 weeks some iron-labeled MDA-MB-231 cells persisted in 
the primary tumour indicating that some of the cells were non-proliferative. Of particular interest 
was the observation of iron-labeled MDA-MB-231 cells in lymph nodes. MRI showed signal 
loss in axillary or brachial lymph nodes at 3 or 4 weeks post mammary fat pad cell implantation. 
The presence of iron-positive MDA-MB-231 cells in nodes was validated by confocal 
microscopy; indicating that nonproliferative, or slowly-dividing, cancer cells can leave a primary 
tumour and metastasize to the lymph node.61 This paper showed that the proliferative status of 
cancer cells can be evaluated by the retention of iron nanoparticles with cellular MRI.  
In this thesis we will employ similar techniques to investigate the use of 3D cellular MRI for in 
vivo monitoring of the development of 4T1 and 4T1 Y5R-KD primary mammary fat pad tumors, 
proliferative status and the incidence of metastases.  
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1.12 Objectives, Specific Aim and Hypotheses 
The overall objective of this thesis was to elucidate the impact of the NPY-Y5R as a system that 
mediates breast cancer development and to develop an in vivo model in which the contributions 
of Y5R could be functionally studied. 
1.12.1 Specific Aims 
1. Evaluate the heterogeneity of expression of Y5R of breast cancer cell lines of various 
levels of aggression. 
2. Investigate the proliferative potential of the breast cancer cell lines induced by various 
concentrations of NPY. Understand the specific role of Y5R in proliferation via receptor 
blockade.   
3. Establish and validate a 4T1- Y5R knockdown to assess resulting phenotypic alterations 
that contribute to breast cancer carcinogenesis.  
4. Utilize cellular MRI for the in vivo evaluation of the influence of Y5R on primary tumour 
growth, proliferation and metastasis.  
1.12.2 Overall Hypothesis 
Neuropeptide Y-Y5R is a factor that promotes breast cancer tumourigenicity and metastasis. 
1.12.2.1 Specific Hypotheses 
1. The metastatic potential coordinates with the Y5R expression of the respective cell lines. 
Therefore, metastatic strains of breast cancer with express more Y5R.  
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2. NPY stimulates the proliferation of breast cancer cell lines. Y5R antagonism will inhibit 
Neuropeptide Y- stimulated proliferation. 
3. Knockdown of Y5R will mitigate the proliferative stimulation of NPY. 
4. Knockdown of Y5R will reduce the metastatic burden and inhibit proliferation.  
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Chapter 2- Neuropeptide Y-Y5R as a Mediating Factor of Breast 
Cancer 
2.1 Introduction 
In Canada, one in nine females is expected develop breast cancer in her life time.1 The 
98.8% 5- year survival rate of localized breast cancer drops to 26.3% when the breast cancer has 
metastasized.2 Common sites of breast cancer metastasis are the lungs, liver, bone, and brain.3 In 
triple negative breast cancers, negative for the estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor 2 (HER-2), treatment with classic hormone 
therapy is futile. Therefore, a therapy for a novel target to treat triple-negative breast cancer is 
required. 
Behavioural and emotional stress has been implicated in breast cancer progression and 
metastasis. Studies have demonstrated a correlation between elevated stress levels and poor 
prognosis and survival in patients with breast cancer.4–8 Furthermore, there has been documented 
support of prolonged survival in breast cancer patients who receive therapeutic emotional 
support.6,9,10 Swim stress, surgical stress, social confrontation, and hypothermia in animal stress 
models have been shown to promote lung metastasis from injected breast cancer cells.11–14  
Neuropeptide Y is a sympathetic neurotransmitter peripherally released from sympathetic 
nerves, adrenal medulla and platelets.15 The lateral and anterior cutaneous branches of the second 
and sixth intercostal nerves sympathetically innervate the mammary gland, smooth muscle of the 
areola, skin, and breast vessels.16 NPY is released in greater quantities during chronic stress and 
in response to a life-threatening stressor. In this respect, the breast microenvironment is 
susceptible to the alterations in NPY flux induced by stress. This susceptibility has the potential 
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to negatively impact women with family histories of breast cancer who have an increased basal 
release of sympathetic neurotransmitters in response to daily stressors.17  
NPY elicits its effects by binding and activating Gi- protein coupled receptors (GPCR), 
Neuropeptide Y1R-Y6R. Neuropeptide Y5R is expressed in cancer cell lines including breast 
and brain xenograft models.12-15 The Jackson lab has studied the influence of Neuropeptide Y in 
the murine 4T1 breast cancer cell line. The 4T1 cell line aggressively metastasizes to lungs, liver, 
bone and brain primarily hematogenously.20 They have shown that NPY supports proliferation, 
migration, angiogenesis, and metastasis of 4T1 cells. Furthermore, they have shown that Y5R 
activation significantly contributes to these NPY supported cancerous processes.21,22 Although 
the contribution of the NPY and Y5R has been well characterized in the 4T1 cell line, the 
influence of this system has yet to be characterized in cell lines of various metastatic potentials.  
In this thesis, we aim to expand on the previous findings from the Jackson lab to further 
elucidate the impact of the NPY-Y5R as a system that mediates breast cancer metastasis and to 
develop an in vivo model in which the contributions of Y5R can be functionally studied. To meet 
this objective, we have investigated three cell lines with various metastatic capacities and 
investigated the role of Y5R and NPY-stimulated proliferation. Furthermore, we investigated the 
role of Y5R in aggressively metastasizing 4T1 cells by knocking down Y5R expression 
facilitated by shRNA. Using this knockdown, we evaluate the contribution of Y5R to breast 
cancer cell proliferation in vitro and metastasis in vivo. To study this in vivo we used cellular 
MRI to monitor tumour growth and metastasis and track the fate of iron oxide pre-labeled cancer 
cells  
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If a direct link can be established between the physiological stress response and breast 
cancer progression, NPY and its Y5 receptor could be potential therapeutic targets to combat 
breast cancer metastasis. 
2.2 Methods 
2.2.1 IN VITRO EXPERIMENTS 
In vitro experiments were conducted to characterize the expression of Y5R in three cell lines of 
various metastatic potential; 67NR, 168 FARN, and 4T1. The proliferation of each cell line was 
investigated under the stimulation of NPY and Y5R blockade, to elucidate the specific 
contribution of the receptor.  
2.2.1.1 Cell Culture 
4T1 cells were a gift from Dr. Fred Miller (Wayne State University, Michigan USA), 
168FARN and 67NR cells, were a gift from Dr. Ann Chambers (London Health Sciences Centre, 
London, Canada). The 67NR, 168 FARN, and 4T1 cell lines originate from the same murine 
mammary fat pad tumour with different metastatic potentials.49 67NR cells solely proliferate in 
the mammary fat pad and do not intravasate into vessels to metastasize. 168FARN cells have the 
capacity to disseminate to the lymph node but do not metastasize to other parts of the body. 4T1 
cells are able to aggressively metastasize from the primary mammary fatpad to the lungs, liver, 
bone and brain.  
Cells were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM) 
supplemented with 10% sterile FBS. Cells were incubated at 37oC and 5% carbon dioxide. At 
approximately 80% confluency, cells were washed with PBS and passaged using 0.25% trypsin-
EDTA treatment for dissociation. 
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2.2.1.2 Development of a 4T1-Y5R Knockdown Cell Line 
A 4T1 Y5R-Knockdown (KD) cell line was established to directly study the role of Y5R 
in an aggressively metastasizing breast cancer cell line. 3x105 4T1 cells were plated in a 6 well 
plate and grown to 50% confluence. Y5R specific shRNA green fluorescent protein positive 
(GFP+) expression plasmids (OriGene NM 006174) were suspended in 50µl of ddH2O to a final 
concentration of 100ng/µl. 1µg of shRNA was diluted in 250µl of Opti-MEM I (Gibco 51985). 
3µl of LipofectamineTM 3000 (ThermoFisher Scientific, Waltham, MA, USA) was added to 
diluted shRNA and incubated for 15 minutes at room temperature.  Cells were incubated with the 
shRNA mixture at 37oC and 5% CO2 for 72h. These transfection steps toward establishing the 
4T1 Y5R-KD cell line were completed by Dr. Phil Medeiros, a previous PhD student in the 
Jackson lab. 
Cells that had previously been transfected with Y5R specific shRNA GFP+ expression 
plasmids were thawed, re-suspended and analyzed for GFP. Cells were re- suspended in 1% FBS 
in PBS and were then analyzed for live GFP+ containing cells by fluorescent-activated cell 
sorting (FACS). To determine viability, cells were stained with 7-Aminoactinomycin D (7AAD) 
viability dye (ThermoFisher Scientific, Waltham, MA, USA) for 10 minutes on ice prior to 
sorting.  FACS was conducted on a FACSAriaIII system (BD Biosciences, Mississauga, ON, 
Canada) using a 100µm filter and parental 4T1 cells were used as a negative control.  
 One cell was seeded per well in four 96 well- plates using a FACSAriaIII to develop 
clonal colonies. Fluorescent colonies were trypsinized and expanded for GFP positive purity 
analysis and sorting. Purity greater than 95% prior to sort was deemed as stable transfection. 
FACS data was analyzed using BD FACSDiva Shortware version 8.0.1. 
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2.2.1.3 Immunocytochemistry 
To determine the presence and localization of Y5R, immunocytochemistry was 
conducted on 67NR, 168FARN, 4T1 and 4T1 Y5R-KD cells. 105 cells of each strain were grown 
on sterile glass coverslips for 48hr, then fixed in ice-cold 4% paraformaldehyde for 15 min. Cells 
were washed in ice- cold phosphate-buffered saline (PBS; 2.68mM KCL, 1.46mMKH2PO4, 
137mM Nal and 6.48mM Na2HPO4) and permeabilized in 0.25% (v/v) Triton-X 100 (in PBS) for 
20 min at room temperature followed by PBS washes. Following 10 min blocking in 1.5% 
normal goat serum (in PBS), excess blocking reagent was removed, and replaced with 2ml of 
diluted (1:1000) primary antibody specific to NPY Y5R (Cat no. ab133757 Abcam, San 
Francisco, CA, USA) for 1hr at room temperature. Cells were washed, incubated in secondary 
antibody (biotinylated goat anti-rabbit secondary, 4µg/ml in 0.1% blocking serum in PBS) for 30 
minutes at room temperature, washed and incubated in 1:1 avidin:biotin complex (ABC) 
(Vectastain Elite ABC® Kit (Standard), Cat. no. PK-6100, Vector Laboratories Inc., 
Burlingame, CA) solution for 30 min. After washing, cells were incubated in 3,3 
diaminobenzidine (DAB Peroxidase Substrate Kit, 3,3’-diaminobenzidine, Cat. no. SK-4100, 
Vector Laboratories Inc., Burlingame, CA) for 8 minutes, rinsed, cleared and mounted.  
2.2.1.4 Western Blot Analysis 
To quantify and compare the expression of Y5R between 67NR, 168FARN, 4T1, and 
4T1 Y5R-KD cell lines, Western Blot analysis was conducted. Cultured cells from a 75cm2 flask 
were washed in ice cold PBS and then lysed in 1.5ml RIPA lysis buffer containing protease 
inhibitors (104mM AEBSF, 80 µM aprotinin, 2.1 mM leupeptin, 3.6 mM bestatin, 1.5 mM 
pepstatin A, 1.4 mM E-64). Cells were scraped and then lysed using a 27- gauge needle with 
syringe. Cells were centrifuged for 10 minutes at 14,000 rpm at 4oC. Supernatant was collected 
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and stored at -20oc until protein concentration was determined.   
A Bradford assay (Bradford, 1976) was performed to determine total protein 
concentration of samples. Fifteen micrograms of protein from each sample were loaded on a 4% 
to 12% gradient gel and separated by SDS- PAGE. After electrophoresis, proteins were 
transferred at a constant voltage to polyvinylidene fluoride membranes. Membranes were 
blocked in 5% Bovine Serum Albumin (BSA) in Tris- Buffered Saline + Tween 20 (0.5%) 
(TTBS) for 1 hr. Membranes were then incubated in primary monoclonal antibody specific to 
NPY Y5R (Cat no. ab133757 Abcam, San Francisco, CA, USA) in 5% BSA- TTBS at a 
concentration of 1:1000 at 4oC overnight. Membranes were washed three times in TTBS then 
incubated in secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit IgD, 
1:20000) in 2% BSA-TTBS for 1hr. Membranes were washed three times and bands were 
detected using an Immun- Star WesternC© chemilluminescent kit (Bio- Rad, Hercules, CA, 
USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Membranes 
were washed, stained for total protein using Coomassie Brilliant Blue and imaged using the 
ChemiDoc XRS. Densitometric band quantification was performed with Quantity One 1-D 
Analysis Software (Bio-Rad, Hercules, CA, USA). Y5R band intensity was normalized to the 
respective average lane signal intensity from Coomassie Brilliant Blue staining.  
2.2.1.5 Cell Proliferation 
In vitro MTS assays were conducted to investigate the effect of NPY on 67NR, 168 
FARN and 4T1 cell line proliferation. One thousand two hundred and fifty viable cells were 
seeded per well of 96- well plates for 24 hrs in DMEM supplemented with 10% FBS. After 24hrs 
media was replaced with experimental medium (DMEM + 2% FBS) containing 10-11 to 10-6M 
NPY (Tocris, Minneapolis, MN, USA) or scrambled 10-6M NPY. The proliferative effect of 
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NPY was tested using an MTS (3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium) based assay (CellTiter 96 AQueous One Solution, Madison, WI, 
USA). Absorbance of the wells at 490nm was measured after 24hr of NPY treatment. These 
experiments were conducted on 67NR, 168FARN and 4T1 cells in triplicate (per concentration) 
and repeated three times.  
Receptor antagonist experiments were conducted to confirm Y5R- mediated proliferation 
induced by NPY. Twenty- four hours after cells were seeded, experimental media containing 
NPY (10-6M) and Y5R- specific antagonist, L-152 804 (10-4M), was added and cell proliferation 
was measured at 24hrs. Drugs were reconstituted in PBS and all treatments were compared to 
control cells that were incubated in media without the addition of drugs.  
2.2.1.6 Statistics 
Statistical analysis was performed using GraphPad software, data are presented as mean 
± SEM. Non-linear regression analysis was performed on proliferation assays. Statistical 
differences between cell lines for Western blots and between treatments for proliferation assays 
were evaluated by one-way ANOVA, followed by Tukey's HSD test. The level of statistical 
probability was set at p < 0.05. 
 
2.2.2 IN VIVO EXPERIMENTS 
In vivo experiments were conducted on the aggressively metastasizing 4T1 strain and the 
4T1 Y5R-KD strain in order to elucidate the role of Y5R in tumourigenicity and metastasis 
longitudinally in a biologically relevant murine model.  
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2.2.2.1 Iron- Oxide Cell Labeling for Imaging 
To allow cancer cells to be visualized by MRI, 2x106 4T1 or 4T1 Y5R KD cells were 
plated in 75cm2 flask in 10ml of high glucose DMEM supplemented with 10% sterile FBS and 
were incubated for 24 hours at 37oC and 5% carbon dioxide. Cells were then incubated with the 
same media containing 50µg/ml flash red fluorescent micron-sized superparamagnetic iron oxide 
particles (MPIO) (Bangs Laboratories Inc., Fishers, IN) for 24h. Cells were washed three times 
with 10ml of 37oC HBSS and trypsinized with 0.25% trypsin-EDTA. Cells were centrifuged for 
5 minutes at 1000RPM, the supernatant was aspirated and cells were re-suspended in 12 ml of 
HBSS three times. Cells were concentrated to 6x106/ml for injection.  
To verify cell labeling, 3x105 cells were cytospun onto a slide and fixed in 3:1 methanol: 
glacial acetic acid. Cells were stained with 1% potassium hexacyano-ferrate (III) trihydrate in 
1% HCl for 30 minutes. Cells were washed in dH2O prior to counterstain with Nuclear fast red. 
Cells were washed and dehydrated in increasing concentrations of 75%, 95%, and 100% ethanol 
and xylene prior to being mounted.  
2.2.2.2 Animal Model 
To establish orthotopic tumours, 3 x 105 MPIO labeled 4T1 cells (n=8) or 4T1 Y5R KD 
GFP positive cells (n=9) were injected into the inguinal mammary fat pad of female 6-8 week  
BALB/c mice (Charles River Laboratory).  
2.2.2.3 Magnetic Resonance Imaging 
All imaging was performed on 3T MRI scanner (General Electric Medical Scanner, 
Milwaukee, WI) using a custom- built gradient coil insert with an inner diameter of 17.5cm, 
maximum gradient strength of 500mT/m and a peak slew rate of 3,000T/m/s, and a custom 
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solenoidal whole- mouse body radiofrequency (RF) coil 4cm in length and 3cm in diameter. 
Mice were anaesthetized with isoflurane (2% in oxygen) and placed prone in the coil, a warm 
saline bag was kept near the RF coil to maintain body temperature, and the mice were wrapped 
with gauze and tape for consistent positioning to minimize motion artefact due to respiration.  
Images were acquired using bSSFP pulse sequence with 200µm isotropic spatial 
resolution. The scan parameters for bSSFP were as follows: repetition time (TR) =6.3ms, echo 
time (TE)=3.15ms, flip angle=35o, bandwidth= +/- 31.25kHz, matrix=250x250, field of view 
(FOV) was 5x2.5cm (30 minutes), 0.2mm slice thickness, 2 signal averages (NEX)=2, RF phase 
cycles=8.  
2.2.2.4 Image Analysis 
Mouse body three dimensional (3D) bSSFP images were assessed for the appearance of 
primary tumours and metastases.  Images were observed in all three orientations (axial, sagittal 
and coronal).  Osirix image analysis software was used to make all measurements from images 
acquired in the study. To calculate the volume of the mammary fat pad tumour from MRI, 
manual segmentation was conducted in each acquired image using the closed polygon tracing 
tool and repulsor tool. Each tumour was segmented as a region of interest (ROI) and total tumour 
volume was calculated by using the ROI volume calculation tool in the software package.  
To calculate the volume of the region of signal hypointensity within the tumours the 
mean signal intensity of the hypointense region was measured and a threshold value (mean signal 
+ 2 standard deviations) was applied to the whole tumor volume. This value was normalized to 
the total tumour volume. All volume data was statistically compared using Graph Pad Prism 
analysis software (GraphPad Software, La Jolla, CA).  
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Primary tumour colour maps were generated by assigning colours to three signal intensity 
values; blue was assigned to voxels with values equal to the mean signal hypointensity +2SD, 
yellow was assigned to voxels with values equal to the mean signal hyperintensity +2SD, and 
green was assigned to the remainder of the tumour voxels.  
2.2.2.5 Histology and Microscopy 
All mice injected with 4T1 cells were euthanized at day 28. Two mice injected with 4T1 
Y5R-KD cells were euthanized on each of days 14 and 21 and five were euthanized at day 28. 
Mice were cardiac perfused with 4% paraformaldehyde. Lungs and tumours were removed and 
immersed in 4% paraformaldehyde for 24 hours followed by increasing concentrations of 10%, 
20%, and 30% sucrose to cryoprotect tissues. Lungs and tumours were embedded in Optimal 
Cutting Temperature medium in a cryomold. Frozen sections were cut with a cryostat (Leica 
Microsystems) with a thickness of 10µm. Tumour sections were cut with 1mm separation 
between samples, starting from what was discerned as the center of the tumour to yield three 
regions of interest. Lung sections were cut through a pair of lungs with 1mm separation between 
samples, starting from what was discerned as an edge of the lung to a midpoint, yielding two 
regions of interest. Three samples were taken at each region of interest for tumours and lungs to 
be stained with Hematoxylin and Eosin (H&E), Perl’s Prussian Blue (PPB) and Nuclear Fast Red 
(NFR), and Immunohistochemistry (IHC). 
2.2.2.6 Hematoxylin and Eosin staining 
 Tumour and lung slides were washed in xylene prior to washes in decreasing 
concentrations of ethanol, 100%, 95%, and 70%. Tissues were washed with dH2O and stained 
with hemaxtoxylin. Tissues were washed with dH2O, acid ethanol, and H2O prior to eosin 
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staining. Tissues were washed and dehydrated in increasing concentrations of 75%, 95%, and 
100% ethanol and xylene prior to being mounted. 
2.2.2.7 Perls’ Prussian Blue and Nuclear Fast Red staining 
 Tumour and lung slides were stained with 1% potassium hexacyano-ferrate (III) 
trihydrate in 1% HCl for 30 minutes. Tissues were washed in dH2O prior to counterstain with 
Nuclear fast red. Tissues were washed and dehydrated in increasing concentrations of 75%, 95%, 
and 100% ethanol and xylene prior to being mounted. 
2.2.2.8 Immunohistochemistry 
 Tumour and lung slides were rehydrated in 1X TBS-T (0.05M Tris Base, 1.8% NaCl, 
0.05% Tween 20, pH 8.4). Tissues were blocked in for 30 minutes at room temperature in 
Protein Block Serum-Free solution (Product no. X0909, Dako, Agilent Technologies, Glostrup, 
Denmark). Tissues were then incubated in primary polyclonal antibody specific to NPY Y5R 
(Cat no. ab137204, Abcam, San Francisco, CA, USA) diluted to 1:50 in 1% bovine serum 
albumin, 1% normal goat serum, in TBS-T for 2hrs at room temperature. Adjacent slices were 
incubated in TBS-T as a negative control. Tissues were washed three times and incubated in goat 
anti-rabbit IgG (H+L) secondary antibody, Alexa Fluor® 568(Cat no. A-11011, Life 
Technologies, Carlsbad, CA)  diluted to 1:500 in 1% bovine serum albumin, 1% normal goat 
serum, in TBST. Slides were washed prior to mounting and visualized with a fluorescence 
microscope.  
2.2.2.9 Statistics 
Statistical analysis was performed using GraphPad software, data are presented as mean 
± SEM. Non-linear regression analysis was performed on mean 3D tumour volume growths and 
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signal void volumes to compare the cell lines. Statistical differences between treatments were 
evaluated by two-way ANOVA, followed by Tukey's HSD test. The level of statistical 
probability was set at p < 0.05. 
2.3 Results 
2.3.1 Y5R Presence and Localization in 67NR, 168FARN, and 4T1 
Immunocytochemistry revealed receptor expression for Y5R in the 67NR, 168FARN, 
and 4T1 cell lines (Figure 2.1). Primarily, nuclear staining was found in the 67NR and 168FARN 
cell lines (Figure 2.1A&B). The 4T1 cell line displayed predominantly membranous and 
cytoplasmic staining in addition to nuclear staining (Figure 2.1C).  
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 A.          Conjugate and Chromagen Control       
  
B.              
 
C.  
  
Figure 2.1 Y5R Immunocytochemistry of 67NR, 168FARN and 4T1 Cells (A. 67NR) 
Positive Y5R staining localized primarily in the nucleus (B. 168FARN) Positive Y5R staining 
localized primarily in the nucleus (C. 4T1) Positive Y5R staining localized primarily in the 
cytoplasm, membrane, and filapodia (Scale bars= 100µm). Conjugate and chromagen control 
was conducted for each cell strain without incubation of the primary Y5R antibody, 
demonstrating minimal background staining.   
 
 41 
2.3.3 Y5R Expression Quantified in 67NR, 168FARN, and 4T1  
Western blots revealed significantly enhanced expression of Y5R in 4T1 cells compared 
to 168FARN and 67NR cells (Figure 2.2). 4T1 expressed nine to twelve times greater levels of 
Y5R than the 67NR and 168FARN cell lines, respectively.  
 
Y5R (52kDa) 
 
Figure 2.2 Basal Y5R Expression of Murine Mammary Fat Pad Carcinoma Cell Lines. 
Western Blot densitometry quantification of respective cell lysates normalized to total protein 
depicting the significantly enhanced Y5R expression of 4T1 cells compared to 168FARN and 
67NR cells. Densitometric data are presented as Y5R expression normalized to total protein 
expression. Data are presented as mean+ SE  (n=3, ** represents a significant difference from 
67NR cells p<0.01, One- way ANOVA).  
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2.3.3 Effect of NPY on Proliferation of 67NR, 168FARN, and 4T1  
The MTS proliferation assay demonstrated that NPY has a stimulatory effect on 
proliferation of the three cell lines, despite variable basal Y5R expression. Without normalization 
of NPY-stimulated proliferation to the respective basal cell strain proliferation, the cell lines had 
a significantly different proliferative response to NPY (p<0.001) (Appendix A). The un-
stimulated proliferation of each cell line differed, supporting the normalization of experimental 
proliferation to basal growth to appropriately investigate the effect of NPY-stimulated 
proliferation. Experimental proliferation was normalized to basal growth by dividing 
experimental proliferation by un-stimulated proliferation of the respective cell line, resulting in a 
control growth of 1 for each cell line (Figure 2.3). Stimulated growth can be observed by values 
greater than 1.0, denoted by the dashed line. When normalized to the control, the proliferation of 
each cell line in response to NPY was not significantly different from each other (p>0.05, Two- 
way ANOVA). NPY concentration had a significant effect on the proliferation of the cell lines 
(p<0.0001, Two- way ANOVA).  
67NR and 168FARN cell proliferation was stimulated by NPY at 10-10M, 10-9, and 10-7M 
(Appendix A). The proliferation appears to drop at concentrations greater than 10-7M. As 
expected, the administered scrambled sequence of NPY, as a negative control, did not stimulate 
proliferation of 67NR and 168FARNcells (Appendix A). The proliferation appears to plateau at 
10-10M of NPY. 4T1 cell proliferation was strongly stimulated by all tested concentrations of 
NPY, except 10-8M, with no apparent plateau in cell growth (Appendix A). The administered 
scrambled sequence of NPY, as a negative control, did not stimulate proliferation of 4T1 cells.  
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C. 
 
Figure 2.3 NPY stimulates proliferation of 67NR, 168FARN, and 4T1 cell lines. NPY 
treatment stimulated an increase in proliferation of all three cell lines at various concentrations 
(NPY 10-11M-10-6M). (A. 67NR) A proliferative effect was stimulated by NPY at 10-10M, 10-9, 
10-7M. (B. 168 FARN) A proliferative effect was stimulated by all tested concentrations of NPY 
and a subtle stimulation by the scrambled form of NPY. (C. 4T1) A proliferative effect was 
stimulated by all tested concentrations of NPY. (All values were statistically compared to 
respective control cell growth, * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001, One- 
way ANOVA).  
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2.3.4 Effect of Y5R blockade on proliferation on 67NR, 168FARN, 4T1 
To determine the specific contribution of Y5R activation in NPY-stimulated 
proliferation, the effect of Y5R blockade by a Y5R- specfic antagonist (L-152804) was examined 
by the MTS proliferation assay. Cells were incubated with media containing NPY (10-6 M) and 
L-152804 (10-4 M). The data were compared to the proliferation of the cells at their peak 
proliferation. 67NR and 168FARN cell proliferation was stimulated most at 10-9 M NPY and 4T1 
cell proliferation was stimulated most at 10-6 M NPY. The Y5R antagonist restored the growth of 
the cells to basal level in all three cell lines as depicted in Figure 2.4.  
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A.       B.  
       
C.  
 
Figure 2.4 Y5R Blockade inhibits NPY stimulated proliferation of 67NR, 168FARN, and 
4T1 cell lines. (A. 67NR) proliferation was significantly stimulated by 10-9M NPY (p<0.05). 
NPY in conjunction with L-152 804 (10-4 M) restored proliferation to control. (B. 168FARN) 
proliferation was significantly stimulated by 10-9M NPY (p<0.05). NPY in conjunction with L-
152 804 (10-4 M) restored proliferation to control.  (C. 4T1) proliferation was significantly 
stimulated by 10-6M NPY (p<0.05). NPY in conjunction with L-152 804 (10-4 M) restored 
proliferation to control.  (All values were statistically compared to respective control cell growth, 
* denotes p<0.05, ** denotes p<0.01, One- way ANOVA). 
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2.3.5 Establishing and validating 4T1 Y5R-Knockdown 
A 4T1 Y5R-Knockdown (KD) was established previously as described above via 
shRNA. Positive vector transfection was selected using flow cytometry to select for GFP+ cells. 
7-AAD viability gating was applied to analyze solely viable cells. Side scatter gate was applied 
to analyze solely single cells. Forward scatter gate was applied to confirm that cells were 
analyzed and not debris of the same size. GFP+ gate was applied to analyze cells that expressed 
GFP. Prior to the final flow cytometry sort, the GFP purity was evaluated at 98.1%. Post flow 
cytometry sort, the GFP purity was evaluated at 98.7%. GFP+ purity with applied gates post 
final sort is shown in Figure 2.5A.  
Western blotting was conducted to confirm the knockdown and revealed a reduction of 
51.67% in the expression of Y5R in the 4T1 Y5R-KD (n=6) compared to the 4T1 (n=6) cell line 
as shown in Figure 5B. Figure 5C shows reduced Y5R expression in the 4T1 Y5R-KD cell line 
in the membrane and cytoplasm compared to the 4T1 cell line. 
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B. 
 
 
 
 
 
 
 
 
 
GFP Expression Intensity GFP Expression Intensity 
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C.             4T1          4T1 Y5R-KD 
      
Figure 2.5 shRNA Y5R Specific Knockdown Decreased Y5R Expression (A. Flow 
Cytometry) 4T1 Y5R KD achieved via shRNA sorted via flow cytometry with a purity of 98.7% 
GFP+. 7-AAD viability gate, side-scatter gate, forward scatter gate and final GFP+ gate applied. 
(B. Western Blot) Densitometry quantification of 4T1 and 4T1 Y5R KD cell lysates normalized 
to total protein depicting the significantly reduced Y5R expression of 4T1 Y5R KD cell line 
compared to the 4T1 cell line. Densitometric data are presented as Y5R expression normalized to 
total protein expression discerned from Coomassie blue staining average lane intensity. Data are 
presented as mean+ SE  (n=6, *** represents a significant difference from 4T1 cell line p<0.001, 
un-paired t-test). (C. Immunocytochemistry of 4T1 and 4T1 Y5R KD) Immunocytochemistry 
of 4T1 and 4T1 Y5R KD cells with decreased cytoplasmic Y5R expression (Scale bar=100µm). 
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2.3.6 Effect of NPY on Proliferation of 4T1 and 4T1 Y5R-KD  
An MTS assay was conducted on the 4T1 and 4T1 Y5R-KD cell line to elucidate the 
proliferative effect that NPY would have on the newly developed strain with a diminished Y5R 
expression. The MTS Assay revealed 4T1 and 4T1 Y5R-KD cell strains proliferate at similar 
rates in the absence of NPY as shown by the control in Figure 6A. As a negative control, a 
scrambled sequence of NPY was applied to both 4T1 and 4T1 Y5R-KD cell lines. The scrambled 
NPY sequence did not induce proliferation of the 4T1 and 4T1 Y5R-KD cell lines as shown in 
Figure 2.6A. This is expected as scrambled NPY does not activate targeted NPY receptors. 4T1 
and 4T1 Y5R-KD cells responded significantly different to NPY stimulation (p<0.05, Two- way 
ANOVA). 4T1 cells achieved a plateau of proliferation at 10-10 M NPY as shown in Figure 2.6B.  
In contrast, the 4T1 Y5R-KD cell line requires a greater concentration of 10-7 M NPY, for cell 
proliferation to plateau as shown in Figure 2.6C. There is a significant difference in proliferation 
between 4T1 and 4T1 Y5R KD cells at concentrations of 10-10 M (p<0.05), 10-9 M (p<0.05), 10-8 
M (p<0.05), and 10-6 M (p<0.05) as shown in Figure 2.6A(p<0.05, Two way ANOVA). 4T1 
Y5R-KD cell proliferation is stimulated solely at 10-7 M (p<0.05) as shown in Figure 2.6C, 
compared to 4T1 cells that proliferate at 10-10 M (p<0.05), 10-9 M (p<0.05), 10-7 M (p<0.01), and 
10-6 M (p<0.01) as shown in Figure 2.6B. Therefore, 4T1 Y5R-KD requires more NPY to 
enhance proliferation compared to 4T1 cells.  
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Figure 2.6 MTS Assay of 4T1 and 4T1 Y5R-KD with NPY stimulation (10-11-10-6M) (A. 4T1 
and 4T1 Y5R-KD proliferation) MTS Proliferation Assay demonstrated that without NPY 
stimulation, there is no significant difference in proliferation between 4T1 and 4T1 Y5R KD 
cells. 4T1 and 4T1 Y5R-KD cells proliferate significantly differently in response to NPY 
(p<0.05). The cell line accounted for 40.81% of variation of proliferation in response to NPY 
(p<0.05, Two way ANOVA with repeated measures, n=3). Concentration accounted for 26.91% 
of variation of proliferation in response to NPY (p<0.01, Two way ANOVA with repeated 
measures, n=3). There was a significant difference in proliferation between 4T1 and 4T1 Y5R 
KD cells at concentrations of 10-10 M (p<0.05), 10-9 M (p<0.05), 10-8 M (p<0.05), and 10-6 M 
(p<0.05, Two way ANOVA with repeated measures, n=3). (B. 4T1) MTS Proliferation Assay 
demonstrated that NPY has a stimulatory effect on proliferation 4T1 cells at concentrations of 
10-10 M (p<0.05), 10-9 M (p<0.05), 10-7 M (p<0.01), and 10-6 M (p<0.01) of NPY compared to 
un-stimulated 4T1 cells  (One-way ANOVA with repeated measures, n=3). (C. 4T1 Y5R-KD) 
NPY stimulated proliferation of 4T1 Y5R-KD cells solely at a concentration of 10-9 M compared 
to un-stimulated 4T1 Y5R-KD cells (One-way ANOVA with repeated measures, n=3). 
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2.3.7 Effect of Y5R blockade on proliferation on 4T1 and 4T1 Y5R-KD 
The effect of Y5R blockade by a Y5R- specfic antagonist (L-152804) was examined by 
the MTS proliferation assay. Cells were incubated with media containing NPY (10-6 M) and L-
152804 (10-4 M). The Y5R antagonist restored the growth of the cells to basal level in 4T1 cells 
as shown in Figure 2.7A. There was no significant difference in the proliferation of 4T1 Y5R-
KD cells between control, maximal NPY- stimulated proliferation and maximal NPY in 
conjunction with L-152804 as shown in Figure 2.7B.  
A.             B.  
 
Figure 2.7 MTS Assay of 4T1 and 4T1 Y5R-KD with NPY and Y5R Antagonism. (A. 4T1) 
Proliferation was significantly stimulated by 10-6M NPY (p<0.05). NPY in conjunction with L-
152 804 (10-4 M) restored proliferation to control.  (B. 4T1 Y5R-KD) There was no significant 
difference between treatments in 4T1 Y5R-KD cells (All values were statistically compared to 
respective control cell growth, * denotes p<0.05, One- way ANOVA). 
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2.3.8. Iron oxide labeling of 4T1 and 4T1-Y5R KD cells for injection 
 Prior to orthotopic injection, 4T1 and 4T1 Y5R-KD cells were pre-labeled with MPIOs to 
track proliferative status via iron dilution. The large iron oxide nanoparticle size permits single 
cell tracking with MRI. Figure 2.8 shows iron oxide nanoparticles stained with Perls’ Prussian 
Blue and cell nuclei stained with Nuclear Fast Red of 4T1 cells (Figure 2.8A) and 4T1 Y5R-KD 
cells (Figure 2.8B). Qualitatively, as seen in Figure 2.8, it appears that both 4T1 and 4T1 Y5R-
KD cells were nearly all labeled, prior to injection.  
A.            B.  
  
Figure 2.8 PPB and NFR Staining of 4T1 and 4T1 Y5R-KD Cells (A. 4T1) Nuclei stained 
with Nuclear Fast Red and iron oxide nanoparticles stained with Perl’s Prussian Blue of cells 
injected for MR imaging (B. 4T1 Y5R-KD) Nuclei stained with Nuclear Fast Red and Iron oxide 
nanoparticles stained with Perl’s Prussian Blue of cells injected for MR imaging. 
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2.3.9 In vivo mammary fat pad tumour appearance and volumes 
BALB/c mice were imaged on days 7, 14, 21 and 28 with the bSSFP imaging sequence. 
4T1 and 4T1 Y5R-KD cells were pre-labeled with MPIOs to allow for tracking cells and 
monitoring proliferation in vivo; as cells proliferate the iron is diluted between daughter cells to a 
level below the sensitivity of MRI. The fraction of iron at each time point can be compared 
between the two cell lines to estimate patterns and degree of in vivo cell proliferation.  
Figure 2.9 shows representative MR images of the mouse body at day 14 post 4T1 cell 
injection. The locations of the mammary fat pad tumour are outlined in green. Isovolumetric 
voxels permit visualization of the tumour in the sagittal, coronal and axial orientations without 
distortion. Figure 2.10 shows similar images for a mouse that received 4T1 Y5R KD cells.  In 
both subject groups, signal loss appears within the primary tumour.  
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Figure 2.9 MR Appearance of 4T1 MPIO Pre-labelled Mammary Fat pad Tumour at Day 
14. (A. Sagittal view) H-head, T-tail, B-back, white arrows- lungs, white arrow head- liver, blue 
arrow- muscle. (B. Coronal view) H-head, T-tail, L-left, R-right, white arrow- lung, white arrow 
head- liver. (C. Axial view) Orange arrow head-spine. Tumour is outlined in green in all images. 
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Figure 2.10 MR Appearance of 4T1 Y5R-KD MPIO Pre-labeled Mammary Fat Pad 
Tumour at Day 14. (A. Sagittal view) H-head, T-tail, B-back, white arrow head- liver, blue 
arrow- muscle, blue arrow head-spleen. (B. Coronal view) H-head, T-tail, L-left, R- right, 
white arrow- lung, white arrow head- liver, blue arrow-muscle, orange arrow- lymph node. (C. 
Axial view) Orange arrow head-spine. Tumour is outlined in green in all images. 
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2.3.10 Longitudinal MRI of primary tumour 
Figure 2.11 and 2.12 show representative cropped images of the 4T1 and 4T1 Y5R-KD 
primary mammary fat pad tumours, respectively, at each imaging time point and the 
corresponding signal intensity colour maps. In the colour maps, blue represents regions of signal 
hypointensity (due to iron oxide particles), yellow represents regions of hyperintense signal (due 
to fluid accumulation) and green represents intermediate signal intensities (tumour mass). In all 
mice the tumour size increased over time.  
For all mice with 4T1 tumours (Figure 2.11), a large region of low signal intensity was 
observed in the central part of the tumour at day 7.  Iron appears with low signal intensity in 
bSSFP images, therefore, this observation suggests the presence of iron retaining cells in the 
tumour. Over time, as the tumour increased in size this region of central signal loss decreased in 
size. In images acquired on day 28 subtle regions of signal hyperintensity were apparent in all 
tumours. Fluids appear bright in bSSFP images, therefore, these regions suggest that there is 
accumulation of fluid, possibly due to necrosis, in tumours at this timepoint. 
Images of 4T1 Y5R-KD tumours showed some differences compared to 4T1 tumours 
(Figure 2.12).  Signal loss was again observed in images of the 4T1 Y5R-KD tumours at day 7, 
however, the signal loss was not restricted to the central zone of the tumour.  Instead signal loss 
was observed distributed throughout the tumour mass.  In addition, the total volume of signal 
loss was less in 4T1 Y5R-KD tumours compared to 4T1. Over time, this pattern of signal loss 
persisted. As with 4T1 tumours the region of signal loss decreased over time. In one of the five 
4T1 Y5R-KD mice no signal loss could be detected in the day 28 image of the tumour. In images 
acquired on day 28 regions of signal hyperintensity became apparent. A larger amount of the 4T1 
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Y5R-KD tumours were occupied by signal hyperintensity as compared to 4T1 tumours (Figure 
2.13). 
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Figure 2.11 4T1 Mammary Fat Pad Tumours. MR image and colour map, respectively, of a 
MPIO pre-labeled tumour at days 7, 14, 21, and 28. 
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Figure 2.12 4T1 Y5R KD Mammary Fat Pad Tumours. MR image and colour map, 
respectively, of a MPIO pre-labeled tumour at days 7, 14, 21, and 28. 
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Figure 2.13 Representative 4T1 and 4T1 Y5R-KD tumours at Day 28 Highlighting 
Differences in Amount of Signal Hyperintensity. At day 28, the 4T1 Y5R-KD tumours has 
larger regions of signal hyperintensity compared to 4T1 tumours. Regions of hyperintensity are 
represented with yellow. Green represents intermediate signal intensity and blue represents 
signal hypointensity.  
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2.3.11 Volumes of the primary tumour and signal void regions 
 bSSFP images were collected in 3D, permitting measurement of tumour volume (Figure 
2.14). The tumour volumes measured for the 4T1 and the 4T1 Y5R-KD cell lines were not 
significantly different at days 7, 14, and 21 between cell lines. At day 28 post- cell injection, the 
mean 4T1 tumour volume was significantly greater than the mean 4T1Y5R KD tumour volume 
(p<0.001, Two way ANOVA). This suggests that the tumourigenicity of the two cell lines is 
significantly different (p<0.05, Two way ANOVA). The tumour growth was modeled with an 
exponential equation (Y=Y0 * ek-x ) for the 4T1 cell line (Y0=0.05261, k=0.1113) and the 4T1 
Y5R-KD cell (Y0=0.04209, k=0.1112).  
At day 7, the percentage of the tumours occupied by signal loss was significantly greater 
in 4T1 tumours (16.56+7.89) compared to 4T1 Y5R-KD tumours (8.29+2.48) (p<0.001). This 
was not significantly different at days 14, 21, and 28 (Figure 2.15). The change in signal loss 
over time between the two cell lines is significantly different (p<0.01, Two way ANOVA). A 
one-phase decay (Y=Y0 –plateau*e-kx + plateau) was fit to the 4T1 cell line signal void volume 
normalized to tumour volume (Y0 =86.35, plateau=1.19, K=0.2446, R2 =0.7704) and the 4T1 
Y5R-KD cell line signal void volume normalized to tumour volume (Y0 =20.11, plateau=0.7975, 
K=0.1354, R2 =0.7116).  
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Figure 2.14 Mean 3D Tumour volume from MRI. The average tumour volume for the 4T1 
and the 4T1 Y5R-KD cell lines were not significantly different at days 7, 14, and 21. 4T1 Y5R 
KD tumours were significantly smaller than 4T1 tumours at day 28 (p<0.001, Two way 
ANOVA). Tumourigenicity of the two cell lines is significantly different (p<0.05, Two way 
ANOVA). Tumour growth was modeled with an exponential equation (Y=Y0 * ek-x ) for the 4T1 
cell line (Y0=0.05261, k=0.1113) and the 4T1 Y5R-KD cell (Y0=0.04209, k=0.111) 
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Figure 2.15 Signal Void Volume Normalized to Tumour Volume. Signal void volume 
normalized to tumour volume was significantly greater in 4T1 tumours than 4T1 Y5R-KD 
tumours at day 7. The iron void volume normalized to tumour volume of the 4T1 cell line and 
the 4T1 Y5R-KD cell line was not significantly different at days 14, 21, and 28 (Figure 12). The 
dilution of iron between the two cell lines is significantly different (p<0.01, Two way ANOVA). 
A one-phase decay (Y=Y0 –plateau*e-kx + plateau) was fit to the 4T1 cell line iron void volume 
normalized to tumour volume (Y0 =86.35, plateau=1.19, K=0.2446, R2 =0.7704) and the 4T1 
Y5R-KD cell line iron void volume normalized to tumour volume (Y0 =20.11, plateau=0.7975, 
K=0.1354, R2 =0.7116).  
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2.3.12 Images of Metastases 
 Both lung and lymph node metastases were observed using MRI.  Lung metastases were 
observed in both 4T1 and 4T1 Y5R-KD mice.  MRI detectable lung metastases were observed as 
early as 21 days post cell implantation in 4T1 mice and in images acquired on day 28 in 4T1 
Y5R-KD mice.  Lung metastases were visible as regions of signal hyperintensity in the lung, 
which normally appears black in MR images because of air.  At day 21, 3 of 4 4T1 mice had 
MRI detectable lung metastases. By day 28, all 4T1 mice had visible lung metastases.  At day 
28, 3 of 5 4T1 Y5R-KD mice had MRI detectable lung metastases.  Lung metastases appeared 
larger in 4T1 mice. Representative images of lung metastases are shown in Figure 2.16.   
Metastases in lymph nodes were only observed in mice that received the 4T1 Y5R-KD 
cells. Nodal metastases were detected in images of 3 of the 5 mice (Figures 2.17-2.19).  
Metastases were detected in either the contralateral or ipsilateral axillary node and in the 
ipsilateral inguinal node.  In Figure 2.17 an axillary node metastasis is shown on the contralateral 
side to the primary tumour (yellow arrow).  Images are shown in all three orientations.   In 
Figure 2.18 an axillary node metastasis is shown on the ipsilateral side to the primary tumour 
(yellow arrow). This metastasis has two lobes.  In Figure 2.18 an inguinal node metastasis is 
visible near the primary tumour. This metastasis is of particular interest since it contains a 
distinct region of signal void. Unfortunately in this study the nodes were not recovered for 
histological assessment.  
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Figure 2.16 MR Images of Representative Lung Metastases. Sagittal image slices of mice 
bodies showing MRI detectable lung metastases (white arrow) as regions of signal hyperintensity 
on black lungs (A. 4T1, day 21) Representative lung metastases found in 3 of 4 4T1 mice at day 
21. (B and C. 4T1, Day 28) Representative lung metastases found in all 4 4T1 mice at day 28. 
(D. 4T1 Y5R-KD, day 21) Representative lung images demonstrating lack of metastases at day 
21 in 4T1 Y5R-KD mice. (E and F. 4T1 Y5R-KD, Day 28) Representative lung metastases 
found in 3 of 5 4T1 mice at day 28.  
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A.            B. 
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Figure 2.17 MR Images of Contralateral Axillary Lymph Node in 4T1 Y5R-KD Mouse at 
Day 28. (A. Coronal view) Enlarged axillary lymph node (white arrow) (B. Axial view) Enlarge 
axillary lymph node (white arrow) (C. Sagittal view) Enlarged contralateral axillary lymph node 
(white arrow) with heterogeneous mammary fat pad 4T1 Y5R-KD primary tumour (yellow 
arrow) with speckled signal voids and necrotic core.  
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A.          B. 
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Figure 2.18 MR Images of Ipsilateral Axillary Lymph Node in 4T1 Y5R-KD Mouse at Day 
28. (A. Coronal view) Enlarged axillary lymph node with two lobes (white arrows) (B. Axial 
view) Enlarge axillary lymph node (white arrow) (C. Sagittal view) Enlarged ipsilateral axillary 
lymph node (white arrow) with heterogeneous mammary fat pad 4T1 Y5R-KD primary tumour 
(yellow arrow) with speckled signal voids and necrotic core.  
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A.          B. 
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Figure 2.19 MR Images of Inguinal Lymph Node in 4T1 Y5R-KD Mouse at Day 28. (A. 
Coronal view) Inguinal lymph node with distinct signal void (white arrow) (B. Axial view) 
Inguinal lymph node with distinct signal void (white arrow) (C. Sagittal view) Inguinal lymph 
node with distinct signal void (white arrow) neighbouring heterogeneous mammary fat pad 4T1 
Y5R-KD primary tumour (yellow arrow) with hypointense ulceration.  
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2.3.13 Histology of primary tumours 
Primary mammary fat pad tumours were sectioned and stained with H&E and PPB&NFR 
to visualize tumour morphology and identify iron oxide nanoparticle localization, respectively. 
Tumors from both cell lines had similar histological appearances. Figure 2.20 shows 
representative H&E stained sections of 4T1 and 4T1 Y5R-KD tumors at Day 28. Examination of 
the tumors revealed that they frequently contained regions of low cell density, consistent with the 
heterogeneous signal in MR images. Signal hyperintensity in bSSFP images represents the 
presence of fluid or fat accumulation, as previously shown in Figure 2.13. Examination of H&E 
revealed necrotic zones in both tumour types.  
Figure 2.21 shows representative PPB stained sections of 4T1 and 4T1 Y5R-KD tumors 
at Day 28. Figures 2.21A-C shows the PPB-positive cells in a section from a 4T1 tumour and the 
corresponding mouse MRI.  PPB-positive cells were typically located centrally within the 
tumour section, which agreed well with observations from MRI (2.21C). Figure 2.21D&E show 
PPB staining in a section from a 4T1 Y5R-KD tumour at day 14 and the corresponding MRI. 
PPB staining was rarely observed in the small sample of day 28 4T1 Y5R-KD tumour sections 
we examined. 
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Figure 2.20 Representative H&E of 4T1 and 4T1 Y5R-KD primary tumours with necrosis 
at Day 28. Necrosis (denoted by black arrows) was found in both 4T1 and 4T1 Y5R-KD 
tumours at Day 28. (A and B.) H&E of 4T1 tumour. Scale bar for A= 300µm. Scale bar for B= 
200µm (C and D.) H& E of 4T1 Y5R-KD tumour. Scale bar for C= 300µm. Scale bar for D= 
200µm 
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A.          B.       C. 
 
 
 
 
 
 
 
D.          E.     
 
 
 
 
 
 
 
 
Figure 2.21 Representative PPB and NFR of 4T1 and 4T1 Y5R-KD Primary Tumours with 
Corresponding MR images. (A and B. 4T1 PPB&NFR) Iron appears blue with PPB staining. 
A&B show positive PPB staining in a 4T1 tumour at Day 28 which is concentrated at the core of 
the tumour. Scale bar for A= 50µm. Scale bar for B= 200µm (C.4T1 MR) Sagittal MR image 
depicting hypointensity concentrated at the core of the tumour. Tumour is outlined in green. (D. 
4T1 Y5R-KD PPB&NFR) Positive PPB staining in a 4T1 Y5R-KD tumour at Day 14. Scale bar 
for C= 200µm. (E. 4T1 Y5R-KD MR) Sagittal MR image depicting hypointensity distributed 
throughout the tumour. Tumour is outlined in green. 
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2.3.14 Y5R Immunohistochemistry of primary tumour 
 Immunohistochemistry (IHC) was conducted on tumours resected at days 14, 21, and 28 
in the 4T1 Y5R-KD model and at day 28 in the 4T1 model to evaluate the contribution of Y5R to 
tumour development. Optimization IHC was conducted on control BALB/c brains and the 
negative control, without the Y5R primary antibody, displayed no observable fluorescence 
(Appendix B). Figure 2.22A shows subtle Y5R expression at the edge of the tumour in the 4T1 
Y5R-KD model at day 14, there is no observable Y5R expression in the core of the tumour at 
this time point. Figure 2.22B shows a diffuse distribution of Y5R in the 4T1 Y5R-KD model at 
day 21 throughout the tumour with enhancement at the edge of the tumour. Figure 2.22C shows a 
homogeneous distribution of Y5R in the 4T1 Y5R-KD tumour at day 28 with subtle 
enhancement at the edge of the tumour. Figure 2.20C Y5R in the 4T1 Y5R-KD model at day 28 
is comparable to the Y5R expression in the 4T1 model at day 28 in Figure 2.22D. The 4T1 
tumour at day 28 has high Y5R expression throughout the tumour and is enhanced at the tumour 
edge.  
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Figure 2.22 Y5R-IHC of primary MFP tumour. (A. 4T1 Y5R-KD day 14) Subtle 
fluorescence at edge of tumour. (B. 4T1 Y5R-KD day 21) Diffuse fluorescence throughout the 
tumour compared to the edge. (C. 4T1 Y5R-KD day 28) Enhanced Y5R fluorescence 
distributed throughout the tumour. (D. 4T1 day 28) Y5R fluorescence present throughout the 
tumour and emphasized at the edge of the tumour. 
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2.3.15 Histology of Lung Metastases 
  Lungs were stained with Hematoxylin and Eosin (H&E) to evaluate metastatic burden 
from the primary MFP tumour. Fluorescent immunohistochemitry, targeting Y5R, was 
conducted to qualitatively assess the expression of Y5R in lung metastases. Figure 2.23 shows 
matched H&E and Y5R IHC of a metastasis in the 4T1 model. In figure 2.23A, Y5R IHC 
revealed less Y5R fluorescence in the metastasis, compared to surrounding Y5R fluorescence of 
lung parenchyma. Figure 2.23C reveals that the Y5R fluorescence of this metastasis is 
comparable to the Y5R fluorescence to the surrounding lung parenchyma.  
 Figure 2.24A and B show matched H&E and Y5R IHC of a metastasis in the 4T1 Y5R-
KD model. Similar to the 4T1 model, Y5R IHC revealed some metastases, which possessed less 
Y5R fluorescence, compared to surrounding Y5R fluorescence of lung parenchyma (2.24A). The 
MRI of this lung is shown in Figure 2.24C. Figure 2.24D depicts a metastasis situated near a 
vessel. The matched Y5R IHC reveals in Figure 2.24E that this metastasis has similar 
fluorescence to surrounding Y5R fluorescence of the lung parenchyma. As qualitatively assessed 
by immunohistochemistry, metastases from both 4T1 and 4T1 Y5R-KD tumours had less or 
similar Y5R expression in comparison to the high expression of Y5R in lung parenchyma.  
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Figure 2.23 4T1 Lung Metastases at Day 28. All metastases are denoted by arrows. 
Representative H&E and matched Y5R IHC of metastases in lungs (Scale bars=200µm) (A.) 
H&E displays lung metastases (B.) Matched Y5R IHC to A. demonstrates less Y5R expression 
in the metastases in contrast with surrounding high Y5R expression in lung parenchyma. (C.) 
H&E displays lung metastases and (D.) Matched Y5R IHC to C. demonstrates equal Y5R 
expression in the metastases in contrast with surrounding high Y5R expression in lung 
parenchyma. 
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Figure 2.24 4T1 Y5R-KD Lung Metastases at Day 28. All metastases are denoted by arrows. 
(Scale bars=200µm) (A.) H&E stained lung tissue (B.) Matched Y5R IHC to A. demonstrates 
less Y5R expression in the metastases in contrast with surrounding high Y5R expression in lung 
parenchyma. (C.) Representative MRI of lung metastases. (D.) H&E displays lung metastases 
adjacent to a vessel (arrowhead) and (E.) Matched Y5R IHC to D. demonstrates enhanced Y5R 
expression in the metastases in contrast with surrounding Y5R expression in lungs.  
 78 
2.3.16 Recovery of Y5R in 4T1 Y5R-KD in vitro 
4T1 and 4T1 Y5R-KD cells were grown for 28 days in vitro to evaluate the stability of 
the 4T1 Y5R-KD. Western blotting was conducted on 4T1 and 4T1 Y5R-KD cell lysates. Cells 
were analyzed after their seventh passage for Y5R expression. Band intensity was evaluated 
using densitometry and was normalized to the average lane intensity with Coomassie blue 
membrane staining. Figure 2.24 demonstrates that 4T1 and 4T1 Y5R-KD cells did not have 
significantly different Y5R expression after 28 days of growth in vitro (p>0.05, Unpaired t-test).    
 
                      
Figure 2.25 Western Blot densitometry quantification of 4T1 and 4T1 Y5R KD cell lysates 
normalized to total protein depicting the no significant difference in Y5R expression between the 
4T1 and 4T1 Y5R-KD cell line. Densitometric data are presented as Y5R expression normalized 
to total protein expression discerned from Coomassie blue staining average lane intensity. Data 
are presented as mean+ SE  (n=3). 
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2.3.4 Discussion 
Understanding the interactions between tumour cells and their microenvironment that 
enhance carcinogenesis and metastases is key to new paradigms for treating cancer. This study is 
the first to our knowledge that has illustrated the variable expression of the Neuropeptide Y5 
Receptor (Y5R) to coordinate with the varying metastatic potential of different breast cancer 
models. Furthermore, this is the first study to reveal the potential role of cytoplasmic localization 
of Y5R in a breast cancer cell strain with the propensity to metastasize. Using cellular MRI, this 
study has shown the contribution of Y5R in vivo on tumourigenicity and metastasis in an 
immune competent model.  
The 4T1-derived murine mammary carcinoma cell lines are syngeneic immune 
competent models and thereby permit a biologically relevant evaluation of cancer. Identification 
of specific biomarkers indicative of metastatic ability would be ideal to determine the fate and 
risk potential of cancer cells. The Jackson lab has previously confirmed the presence of Y5R in 
the 4T1 cell line.22 In this study, immunocytochemistry confirmed that Y5R is expressed in the 
67NR, 168FARN, and 4T1 cell lines, providing the impetus to quantify the expression of Y5R in 
the respective strains with Western blot analysis. As hypothesized, metastatic 4T1 breast cancer 
cells expressed significantly more Y5R than non-metastasizing 67NR and 168FARN cell lines. 
This finding suggests that the expression of Y5R coordinates with metastatic potential of breast 
cancer strains. Sheriff et al. have also found Y5R in estrogen receptor positive and negative 
human breast carcinoma cell lines, demonstrating the potential role of Y5R in both estrogen 
receptor positive and negative models.27 
Despite variable expression of Y5R in each of the cell strains, Neuropeptide Y 
significantly stimulated proliferation of all three studied breast cancer cell lines. This finding 
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demonstrates the robust mitogenic properties of Neuropeptide Y. Stressful conditions, such as 
cold or restraint stress, significantly enhance the circulating plasma levels in mice from basal 
levels of the order 10-11 M to approaching 10-10 M in stress conditions.28 Additionally, the 
Jackson lab has demonstrated robust NPY expression in sympathetically innervated 4T1 
mammary fat pad tumours.29 Further studies should be conducted in vivo, to elucidate if NPY is 
sufficient to accelerate proliferation of the slowly proliferating 67NR cell strain in basal and 
stressed conditions.  
Previous experiments have demonstrated that Neuropeptide Y in conjunction with Y1R 
or Y2R antagonism does not inhibit proliferation in 4T1 cells, in contrast to Y5R antagonism, 
which abolishes Neuropeptide Y stimulated proliferation.22 Y5R antagonism has also been 
shown to abolish the proliferative effect of NPY in triple negative human breast carcinoma BT-
549, estrogen positive human breast carcinoma MCF-7, and SK-N-BE2 neuroblastoma.27,30 
Similarly, this study demonstrated that Y5R antagonism eliminated the proliferative effects of 
Neuropeptide Y of the 67NR, 168FARN and 4T1 cell line.  
In a previous study by the Jackson lab examining the pro-angiogenic effects of NPY on 
the 4T1 breast cancer cells, twenty four hours of NPY treatment caused a marked increase in 
VEGF expression in 4T1 cells compared to non- treated controls, as a negative control, 
scrambled NPY treatment had no effect on VEGF expression.21 As well, in a study of various 
human breast carcinoma cell lines in vitro, no NPY mRNA could be detected.27 These findings 
suggest that 4T1 cells require the stimulation of NPY released from sympathetic nerves to induce 
Y5R-mediated cancerous properties.  
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Traditionally, GPCRs were considered to reside solely in the cell membrane and elicit 
their effect downstream through secondary effectors, however this notion has been dismissed 
with effects and localization in the nucleus. In fetal and embryonic endothelial cells, active Y1R 
has been found predominantly in the nucleus and nuclear envelope compared to the cytoplasm, 
with the capacity to induce an increase in nuclear Ca2+ upon NPY stimulation, suggesting a 
potential nuclear role in gene expression modulation.31 In a study by Czarnecka et al., brain- 
derived neurotrophic factor (BDNF) increased Y5R expression and triggered internalization of 
Y5R in neuroblastoma cells as a pro-survival technique against cellular stress such as 
chemotherapy. Y5R antagonism inhibited chemo-resistance and sensitized the cells to apoptosis- 
induced chemotherapy.18  
As shown with immunocytochemistry, we found Y5R is expressed predominantly in the 
cytoplasm and membrane in the aggressively metastasizing 4T1 breast cancer strain. In contrast, 
we found that non-metastasizing 67NR and 168FARN breast cancer strains express Y5R 
predominantly in the nucleus. The significance of nuclear Y5R localization requires further 
investigation. The nuclear Y5R localization of 67NR and 168FARN cells could support 
chemoresistance of breast cancer cells, similar to neuroblastoma.18 If basal nuclear receptor 
internalization of the non-metastatic strains mediates inhibition of pro-cancerous genes, 
therapeutic monoclonal Y5R antibodies that induce internalization could be therapeutic for 
metastatic strains. Anti- EGFR and anti- HER2 antibodies that induce receptor internalization 
have been approved for clinical use in oncology.32 Receptor localization of the 67NR and 
168FARN strains post NPY stimulation should be further investigated to understand the role of 
receptor localization. The nuclear Y5R localization of 67NR and 168FARN cells could support 
chemoresistance of breast cancer cells, similar to neuroblastoma.18 Additionally, the capacity of 
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67NR cells to proliferate under certain concentrations of NPY may modulate tumour- supporting 
mitogenic genes to enhance proliferation via nuclear Y5R activation. It should be noted that in 
human breast carcinoma cell line, BT-549 and rat aortic vascular smooth muscle cells, Y5R 
activation was found not be coupled with a change in intracellular Ca2+.27,33 However, NPY and 
Y5R specific agonism inhibits intracellular cAMP accumulation and correlates with proliferation 
of BT-549 cells.27 
MRI has been widely used to study preclinical mouse models of cancer and provides 
excellent 3D anatomic detail and sensitivity to permit tumour size quantification and location, in 
addition to edema, hemorrhage, and necrosis.24 The analysis of volumes over time can provide 
information about growth rates for individual tumors.  Cellular MRI can be achieved by pre-
labeling cells with iron oxide nanoparticles prior to their administration. In this study, we pre-
labelled 4T1 and 4T1 Y5R-KD cells with MPIOs. Labeling with MPIOs has been previously 
shown to have no discernable effect on viability, in vitro proliferation, cell apoptosis, necrosis, or 
in vivo metastasis compared to unlabeled cells.23–25  
Few groups have used cellular MRI to study cancer cells because the iron label is diluted 
over time in proliferative cells. Since the detection of iron-labeled cells by MRI relies on the 
total iron content, eventually the cancer cells will not contain enough iron to be detected as 
signal voids in MRI.  This property can be exploited, however, as slowly-proliferative or 
transiently dormant cells retain iron oxide nanoparticles for longer periods of time than highly 
proliferative cells.26 The Foster lab has previously used cellular MRI to monitor the development 
of iron-labeled primary MDA-MB-231 mammary fat pad tumours and metastasis to the lymph 
nodes.26  
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Similarly, in this thesis we used cellular MRI to monitor the development of iron-labeled 
primary 4T1 and 4T1 Y5R-KD mammary fat pad tumours and metastasis to the lungs and lymph 
nodes. 4T1 Y5R-KD tumours grew significantly slower over four weeks and were significantly 
smaller than 4T1 tumours at day 28. It is noteworthy that the significant difference in tumour 
growth was under the influence of basally released NPY in non- stressed conditions. This 
significant finding highlights the ability of NPY to activate Y5R, resulting in the acceleration of 
in vivo tumour development, independent of chronic or traumatic stress. 
The Foster lab has previously shown that proliferative status of cancer cells can be 
evaluated through MRI through the retention of iron oxide nanoparticles.23,26 In this study, pre-
labeling 4T1 and 4T1- Y5R KD cells prior to implantation permitted evaluation of signal void 
volume and distribution. We found 4T1 Y5R-KD tumours had a significantly smaller signal void 
volume than 4T1 tumours at day 7.  The presence of iron-labeled cells causes signal loss in MR 
images and what is known as a blooming artefact, where the signal void volume is greater than 
the actual volume occupied by iron oxide labeled cells.24 The size of the blooming artefact 
depends on several factors including the total iron content, spatial resolution, magnetic field 
strength, cell type and cell density. The larger void volume measured for 4T1 tumours compared 
to 4T1 Y5R-KD tumours may be due to higher iron content in the tumour.  
The distribution of iron- retaining cells also differed between the two cell lines. The 4T1 
Y5R-KD tumours have a speckled or diffuse distribution of signal voids throughout the tumour, 
in contrast to the centralized signal void in the core of 4T1 tumours.  Cells with similar 
properties tend to remain clustered within tumours.34 This property could account for the 
centralized cluster of slowly proliferating cells in the core of the 4T1 tumour. Furthermore, this 
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property could account for the diffuse clustered aggregation of slowly proliferating iron-retaining 
4T1 Y5R-KD cells that have maintained the knockdown.  
 Using MR imaging, we were able to detect metastases and enlargement of the axillary 
and inguinal lymph nodes in only the 4T1 Y5R-KD mice. The presence of metastases in lymph 
nodes is supported by distinct hypointensity in the inguinal lymph node due to the presence of 
iron oxide nanoparticles disseminated from the primary tumour. Despite the presence of lymph 
node metastases, lung metastases were detected in more 4T1 mice and at an earlier imaging time 
point compared to 4T1 Y5R-KD mice. 4T1 cells metastasize primarily hematogenously and to a 
lesser extent via draining lymph nodes.20 The non-metastatic 168FARN cell line spreads to the 
lymphatics with occasional lung metastases.20 This finding suggests the knockdown of Y5R in 
the 4T1 cell line has the capacity to diminish its aggressive metastatic phenotype to resemble the 
non-metastatic 168FARN cell line.  
Lungs are the most common site of breast cancer metastasis.35 NPY is released directly to 
lungs and has the capacity to elevate pulmonary vascular permeability.36,37 The molecular 
transduction of stress via NPY as a result of enhanced tumour burden should be further explored 
as it may prime the microenvironment for targeted metastasis. This avenue is worth investigation 
due to the high expression of Y5R in the lungs shown with immunohistochemistry. Y5R could 
be an indicator of metastases onset and may play a role in metastases formation. 
The tumour microenvironment at the edge differs from the hypoxic core of the tumour. 
Particularly, tumour associated macrophages (TAMs) play a large role at the invasive edge of 
tumours, to drive invasive phenotypes by stimulating cancer cell migration, metastasis, and 
neovascularization.38 As we have shown with cellular MRI, 4T1 tumours possess an enhanced 
fraction of slowly proliferating iron- retaining cells in the core of the tumour with more 
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aggressively proliferative cells at the oxygenated tumour edge, permitting tumour expansion. 
This property corresponds with the enhanced Y5R expression at the edge of the tumour depicted 
in the immunohistochemistry. This finding suggests that the expansion of the primary tumour is 
mediated by the NPY-Y5R system. As the tumour develops, the formation of the hypoxic core 
supports the mitogenic properties of NPY, as hypoxia activates DPPIV driving Y2R/Y5R 
mediated tumourigenesis as previously established in Ewing sarcoma.19  
The complete contribution of Y5R to tumour development and metastasis is diminished 
with the 4T1 Y5R-KD model due to the recovery of the receptor over time as shown with 
immunohistochemistry. The knockdown of Y5R, as shown with Western blot and ICC, at the 
initial establishment of the cell line, could contribute to the delayed tumour development, 
resulting in a significant decrease in the 4T1 Y5R-KD tumour volume at day 28. If the 
knockdown has the capacity to significantly impede proliferation of 4T1 cells, the subpopulation 
of Y5R+ cells has the opportunity to out-compete the knockdowns. This issue is further 
compounded with in vitro  passaging of cells, where a greater fraction of highly proliferative 
cells would be consequently plated. Given that shRNA achieved a 51% reduction in Y5R, which 
was then recovered over time, this may suggest that Y5R+ positive cells in the 4T1 Y5R-KD 
model could have driven establishment of metastases.  
Overall, we report the variable presence and expression of Y5R in the 67NR, 168FARN 
and 4T1 murine breast cancer cell strains for the first time. We have shown that NPY, at 
physiological and pathophysiological levels, can induce potent proliferation mediated through 
Y5R activation of cell lines of variable metastatic potentials and Y5R expression. Furthermore, 
we have illustrated that a transient knockdown of Y5R is sufficient to alter the metastasis of the 
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4T1 cell line. These findings support the role of NPY and Y5R in driving the development of 
breast cancer tumourigenesis and metastasis.  
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Chapter 3- Significance, Limitations, and Future Directions 
3.1 Significance 
Stress should be adequately appreciated as a supporting and mediating factor of carcinogenesis, 
metastasis, and recurrence. The perception of psychosocial and qualitative features of stress 
hinders the additional pathophysiological implications that it should hold.  Studies have 
demonstrated a correlation between elevated stress levels and poor prognosis and survival in 
patients with breast cancer.1–5 Additionally, women with a family history of breast cancer release 
elevated sympathetic neurotransmitters in response to daily stress.6 Therefore, patients 
experiencing normal to chronically elevated stress could be affected by the clinical consequences 
of NPY. 
The American Society of Clinical Oncology recommends therapy for women with metastatic 
breast cancer based on their receptor status (ER, PR, and HER2) and additional biomarkers that 
demonstrate clinical utility that have the potential to guide drug regimens.7 In this respect, we 
believe that Y5R could be a potential biomarker for breast cancer metastatic potential. We found 
that expression of Neuropeptide Y5 Receptor (Y5R) is present in all tested breast cancer lines 
and coordinates with metastatic potential. Cytoplasmic receptor localization and quantity were 
both associated with enhanced metastatic capacity. This finding could hold prognostic utility in 
predicting the likelihood of metastasis. The role of Y5R is not restricted to triple negative breast 
cancers, which have the poorest diagnosis associated with a high recurrence rate.8 The previous 
finding of Y5R in estrogen receptor positive and negative human breast carcinoma cell lines, 
demonstrates the potential role of Y5R in both estrogen receptor positive and negative models.9 
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We found that physiologically relevant levels of NPY have the potential to stimulate significant 
proliferation of breast cancer lines of variable levels of aggression and Y5R expression. If this 
finding is clinically translated to humans, this would provide the impetus to monitor individuals 
with a history of breast cancer or post trauma for recurrence or advancement of metastasis. 
Further research is required to elaborate on our studies to evaluate the potential of NPY as a 
sufficient trigger to induce recurrence by switching growth arrest of dormant breast cancer cells 
to form clinically relevant tumours.  
One of the most significant findings was the alteration of the metastatic cascade via knockdown 
of Y5R in the 4T1 cell line. The five-year survival rate of regional lymph node breast cancer 
metastasis of 85.2% drops to 26.3% with distant breast cancer metastasis.10 Breast cancer cells 
that metastasize haematogenously readily gain access to capillary beds in common distant sites 
of metastasis; lungs, liver, bone and brain. Alternatively, breast cancer cells that metastasize via 
the lymph nodes need to enter the blood circulation in order to gain access to these common 
distant sites of metastasis.11 Y5R antagonism could have the potential to induce a similar 
alteration in the metastatic cascade. 
Two Y5R antagonists are safe to administer to patients, MK-0557 (Merck & Co., Inc.) and S-
2367 (velneperit, Shionogi & Co, Ltd). Both antagonists progressed to phase II trials for obesity, 
but were withdrawn given their lack of clinically meaningful effects, though each had some 
effect on weight loss.12 Therefore, if the therapeutic potential of Y5R antagonism is clinically 
meaningful for breast cancer tumourigenesis and metastasis in humans, the drug safety has 
already been validated.  
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3.2 Limitations 
3.2.1 In vitro MTS proliferation assay 
The MTS proliferation assay is a colourimetric quantification of cell viability based on the 
reduction of MTS tetrazolium compound to a coloured foramazan product.13 The absorbance is 
read and plotted as a gauge of mitochondrial activity and cell viability. A previous study found 
that the MTS assay demonstrated a two-fold underestimation of the anti- proliferative effects of 
polyphenols, in comparison to the direct measures of ATP and DNA methods.14 Direct measures 
that evaluate ATP or DNA could mitigate the limitations of this assay. Furthermore, evaluations 
of doubling would provide a quantitative and translatable measure to evaluate proliferation. 
Therefore, the ability of stable Y5R antagonism to mitigate cancer cell proliferation could be 
enhanced in vivo, compared to our in vitro results. The physiological level of proliferation 
induced by NPY and inhibition via Y5R antagonism requires further investigation.   
3.2.2 Transient Knockdown of Y5R in the 4T1 Cell Line 
shRNA knockdown is achieved through successful vector transfection, transcription of shRNA, 
and subsequent sequestration and degradation of the target mRNA.15 Vector transfection permits 
exploitation of the cellular transcription machinery to transcribe the shRNA. shRNA integrates 
into the endogenous miRNA pathway and induces targeting and degradation by the RNA-
induced silencing complex (RISC).16 Although shRNA has had success in suppressing target 
expression to inhibit carcinogenesis and metastasis in preclinical models in other studies17–19, we 
established a transient knock down of the Y5R in the 4T1 cell line.  
We established a 4T1 Y5R-KD with 98.7% GFP+ expression, confirming high vector 
transfection. We demonstrated 51% knockdown of the receptor with Western Blotting, which 
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was supported by immunocytochemistry of the cell line after one passage. The transient 
knockdown was demonstrated by immunohistochemistry of 4T1 Y5R-KD tumours, which 
depicted receptor recovery at Day 21 and 28. Therefore, the true contribution of Y5R and the 
ability of the receptor’s blockade in mitigating cancerous properties was not fully studied.  
3.2.3 Quantification of signal loss in MR images 
The presence of iron oxide nanoparticles in a magnetic field causes signal dephasing, altering the 
Larmor frequency of surrounding protons and leading to signal loss.20 Quantification of signal 
loss in MR images is difficult because (a) the extent of signal loss produced by iron-labeled cells 
is not linearly related to the iron concentration and (b) the extent of signal loss produced by iron-
labeled cells is much larger than the actual area occupied by the cells; this is known as the 
blooming artefact.  For example, Heyn et al. found a single signal void measured on average six 
voxels, 294µm, and spanned on average three MR slices, 300µm, both dimensions substantially 
larger than the size of the cell ~15µm.21 Since cell number cannot be measured from images of 
signal loss many studies use measurements of the size of the region of signal loss or the degree 
of contrast produced by the iron-labeled cells. In this thesis we measured the signal void volume 
within the tumours.  
Fluorine-19 (19F) MRI is an alternative approach for cell tracking that circumvents many of the 
limitations associated with iron-labeled cell tracking. In comparison to the indirect visualization 
of iron oxide nanoparticles by observed image hypointensity, the spins of 19F nuclei are detected 
directly and image contrast is proportional to the number of 19F atoms per voxel. This property 
mitigates the quantitative concerns with blooming artefacts produced by iron oxide 
nanoparticles. Endogenous fluorine does not contribute to measurable tissue background signal, 
which prevents non-specific contrast agent identification, allowing for direct quantification of 
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labeled cell number. However, compared to iron-labeled cell tracking, sensitivity is low and an 
additional proton MR scan is required to attain anatomical context for the 19F signal.  
3.2.4 Challenges validating signal loss in MRI using PPB staining 
Perls’ Prussian Blue (PPB) was used to stain iron oxide nanoparticles in resected lung and 
tumour slices.  Signal loss, as a result of iron oxide nanoparticles, in tissues can be readily 
identified in MR images due to the blooming artefact. In contrast, PPB staining is a direct 
representation of the iron oxide volume present in a slice. Therefore, small quantities of iron are 
difficult to detect with histology.  In general, it is challenging to compare 10 micron tissue 
section with 200 micron image slices.  Previous work in the Foster lab has shown that summing 
the PPB staining from numerous single tissue sections from a primary tumour will give a better 
picture of the quantity and distribution of PPB-positive cells.22 Due to our limited tissue 
sampling, we did not overlay stained slices, which hindered our ability to localize iron oxide 
nanoparticles with histology in our study. 
3.3 Future Directions 
In Canada, breast cancer is the most frequently diagnosed cancer in females, with 1 in 9 females 
expected to develop breast cancer in their lifetime.23 Metastasis of breast cancer is the culprit of 
dropping the 98.8% 5- year survival rate to 26.3%, supporting the need to further explore 
biomarkers indicative of cancer cell fate.10 This thesis has explored the implications of the 
Neuropeptide Y-Y5R system in breast cancer tumourigenicity and metastasis, providing the 
impetus for further investigation of the role of Y5R cellular localization, influence of NPY and 
Y5R in vitro and in vivo, the NPY- mediated effects of chronic stress in cancer, and translation to 
humans.  
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3.3.1 Localization of Y5R 
The prevalent nuclear localization of Y5R in the 67NR and 168FARN cell strains and 
cytoplasmic localization of Y5R in the 4T1 cell strain is a feature of great interest and should be 
further investigated. The effect of NPY at physiological and pathophysiological levels on 
receptor localization should be examined. Plasma levels of NPY have been measured in both 
stressed and non-stressed conditions, given that NPY has found highly expressed in tumours, it 
would be of great interest to evaluate the NPY levels in a tumour of a stressed subject and 
induced receptor localization at these concentrations.24  
Additionally, further research should examine means of inducing Y5R externalization of the 
67NR and 168FARN cell strains via the establishment and characterization of a Y5R knock-in of 
the 67NR and 168FARN cell strains. It would be of great significance to contrast the chemo-
resistant properties of the cell strains in order to elucidate the benefits of basal nuclear 
localization of Y5R in the 67NR and 168FARN cell strains.  
3.3.2 Influence of NPY in vitro 
In order to support NPY- induced carcinogenesis of the 67NR, 168FARN, and 4T1 cell strains, 
the influence of NPY on migration and angiogenesis could also be assessed, using assays such as 
the modified Boyden chamber and endothelial tube assay, respectively.25,26 These assays have 
been previously and effectively used in the Jackson lab to characterize the 4T1 cell strain under 
the influence of NPY. Additionally, the role of DPPIV, in cleaving NPY to an abbreviated 
Y2/Y5 target, should also be done in order to simulate conditions of the tumour milieu.  
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3.3.3 Blockade of Y5R in vivo 
The transient reduction of Y5R with shRNA should be further expanded upon to evaluate the 
comprehensive contribution of the NPY-Y5R system in driving metastasis. Dr. Phil Medeiros of 
the Jackson lab previously administered oral gavage for 50 days of TAC557, a specific Y5R 
antagonist, resulting in attenuated tumour burden and lung metastasis.27 This method ensures 
longitudinal blockade of the Y5R and would complement longitudinal monitoring of tumour and 
metastases development with cellular MRI. Alternatively, genetic knockout of the Y5R in the 
4T1 cell strain using the CRISPR/cas9 system could be an avenue of further investigation. In a 
comparison of shRNA and CRISPR libraries targeting 93 essential and non-essential genes, 
CRISPR outperformed shRNA due to the presence of more functional constructs, apparent 
absence of off-target effects, better consistency across cell lines and most importantly sustained 
targeting of genes.28  
3.3.4 Chronic stress and mice 
Upon establishment of sustained Y5R blockade in 4T1 cells and/or up-regulation of Y5R in 
67NR or 168FARN cells, the influence of chronic stress resulting in up-regulation of NPY in a 
murine model should be investigated. Baldock et al. induced chronic stress resulting in an NPY 
plasma levels through a weekly rotation of cold stress, restraint stress, and handling stress for six 
weeks that could be administered.29 Due to the extensive tumourigencity and metastasis of the 
4T1 cell line after four weeks that we observed, cell implantation should be done at an optimized 
time where the mouse has been chronically stressed.  
3.3.5 Human tissue studies 
This study has demonstrated the variable expression of Y5R of syngeneic murine strains 
coordinating with metastatic capacity. Evaluation of NPY and Y5R in human tumours and 
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metastases should be investigated. Metastases, recurrence, and survival should also be taken into 
account and analyzed. The implications of these studies would demonstrate the utility of Y5R 
status as a diagnostic marker and Y5R antagonism as a therapy.  
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Appendices  
 
Appendix A. MTS Assay of 67NR, 168FARN and 4T1 Cell Lines with NPY stimulation (10-
11M-10-6M) without normalization to basal growth. (A. 67NR) A proliferative effect was 
stimulated by NPY at 10-10M, 10-9, 10-7M. (B. 168 FARN) A proliferative effect was stimulated 
by NPY at 10-10M, 10-9, 10-7M. (C. 4T1) A proliferative effect was stimulated by NPY at 10-11M, 
10-10M, 10-9, 10-7M, 10-6M. (All values were statistically compared to respective control cell 
growth, * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001, One- way ANOVA). 
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Appendix B. Control Y5R IHC of BALB/c brain. (A. Positive Control) High fluorescence in 
cerebellum showing high Y5R expression (Scale bars=200µm) (A. Positive Control) High 
punctate fluorescence showing high Y5R expression (Scale bars=50µm) (C. Negative Control) 
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